 
 
Official Title:  A Multisite Cluster RCT of the Dementia Symptom Management at 
Home Program   
NCT Number : [STUDY_ID_REMOVED]  
Study Number:  17-[ZIP_CODE]   
Document Type:   Study Protocol and Statistical Analysis Plan  
Date of the 
Document:  • July 27, 2021  
 
 
  Page i 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 28 APR 2017   
   
Tool Revision History: 
 
Version 
Number  Version 
Date  Summary of Revisions Made  
1.0 30 JUNE 
2017  Original version  
1.1 29 SEPT 2017  Change behavioral tool from HABC to the NPI -Q; make clear the endpoint of the NPI -Q is 
individual symptoms, not composite, add DSMB Chair, Cognition screening instrument 
changed from HABC -M to QDRS, QDRS inadvertently left out of section 7.1 on initial 
protocol; Clinicaltrials.gov number added  
1.2 27 NOV 
2017  Changes based on DSMB review of protocol: Remove “Demons tration of efficacy” as a 
means to warrant termination or suspension; Include delirium screening instrument (3D -
CAM); change:  PIs will follow “Standard Clinical Practice” in responding to AE and SAE 
by [CONTACT_457618]/caregiver primary care provider.  Clarified how contamination and 
fidelity monitoring will be performed.  
Add 3D -CAM to the PWD -Dyad Survey Instruments; Change name [CONTACT_457684].  
  
1.[ADDRESS_584604] 2018  Remove Allegiance Home Health as the implementation site for [LOCATION_012] Atlantic 
University. Change “PAINAD or BPI” to include both instruments in assessing PWD for 
pain regardless of the PWD’s QDRS score.  Change Elixhauser comorbidity measure to Charlson comorbidity; Remove caregiver and home health care utilization from visit two.  
1.[ADDRESS_584605] 
been inclu ded in the recruitment process.  Minor formatting edits included.  
1.7 31.JAN  
2020  Added recruitment method for sites: CNS and FIRSTAT.  The updated process will include 
a designated agency point of contact [CONTACT_457619] a daily  potential patient referral  
report  in line with PHI regulations of  newly admitted persons with dementia  aged 65+ who 
live in a pr ivate residence. The report will be made accessible designated research team 
for the purpose of referral submissions. In addition, edits to better clarify reporting process 
of adverse events has also been included . Updated [CONTACT_457690]’s contact [CONTACT_3031].  
1.[ADDRESS_584606] visits to virtual from in -
person. To achieve this, Inclusion criteria additions: internet capabilities; caregiver 8+hrs 
of care management per week; edit retention strategies to replace “magnet” with email visit 
schedule; change the need for subjects to be together for virtual visits 2 -4; add QDRS score 
  Page ii 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 28 APR 2017  of <12 to determine which PWD assessments will be administered; edit informed consent 
process to reflect remote consenting through REDCap; change 3D -CAM to FAM -CAM; 
adds COVID -19 related questions; add electronic gift cards as method of subject 
compensation; clarification provided on method of data collection; change criteria for 
subject disenrollment  
1.[ADDRESS_584607] 
(mail/electr onically). For subjects wishing to have compensation sent  electronically , a 
notification is sent via REDCAP to the subject with the gift c ard’s  claim  numbers . A record 
of the notification is also  saved in the website file repository as a record of distribu tion.   
  
  Page iii 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: [ADDRESS_584608] OF THE DEMENTIA SYMPTOM 
MANAGEMENT AT HOME P ROGRAM 
A phase 3 single 
randomized, multi -site 
evidence- based practice 
quality improvement program controlled trial targeting persons with dementia-
caregiver dyads. 
Principal  
Investigator (Lead Site) : 
 Abraham Aizer Brody, PhD, RN, GNP -BC, FPCN  
NYU Rory Meyers College of Nursing  
[ADDRESS_584609], Room 504 
[LOCATION_001], NY [ZIP_CODE]  
[PHONE_9593]  
[EMAIL_8787]  
Additional Investigators 
(External Site PIs) : 
 
 James E. Galvin, MD, MS  
University of Miami  Miller School of Medicine 
[ADDRESS_584610],  
Miami, FL [ZIP_CODE]  
[PHONE_9594]  
[EMAIL_8788] 
 
Rand Rupper, MD  
University of Utah  
School of Medicine 
C/O George V Whalen VAMC  
VA-Building #2 GRECC 182 
Salt Lake City, UT [ZIP_CODE]  
[PHONE_9595]  
[EMAIL_8789]  
 Robert J. Rosati, PhD  
VNA Health Group  
[ADDRESS_584611], Suite D1  
Holmdel, NJ [ZIP_CODE]  
[PHONE_9596]  
Robert.Rosati@vnahg.o rg 
NYULMC Study  Number:  s17-[ZIP_CODE]  
Funding Sponsor:  National Institutes of Health/National Institute on Aging  
PO: Kristina A McLinden, PhD  
[ADDRESS_584612], Suite 3E500  
Bethesda, MD [ZIP_CODE]- 9205 
[PHONE_9597]  
ClinicalTrials.gov 
Number                 [STUDY_ID_REMOVED]  
Initial version:  6-30-17 
Amended:9 -29-17  
Amended:11- 27-17 
Amended: 8 -16-18 
Amended: 10-5- 18 
Amended: 01- 22-19 
Amended: 07- 05-19  
Amended: 01- 31-20 
Amended: 06- 03-20  
Amended:07-12- 21
Study number:  s17-[ZIP_CODE]   Page 1 
Version:  1.9   
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 05 JAN 2017  
 Statement of Compliance  
 
This study will be conducted in accordance with the Code of Federal Regulations on the Protection of 
Human Subjects (45 CFR Part 46), 21 CFR Parts 50, 56, 312, and 812 as applicable, any other applicable 
US government research regulations , and institutional research policies and procedures . The International 
Conference on Harmonis ation (“ICH”) Guideline for Good Clinical Practice (“GCP”) (sometimes referred to 
as “ICH -GCP” or “E6”) as well as the National Clinical Effectiveness Committee Standards for Clinical 
Practice will be applied only to the extent that it is compatible with FDA and DHHS regulations.  The Principal 
Investigator [INVESTIGATOR_7433], or changes to the protocol will take place without prior agreement from the sponsor and documented approval from the Institutional Review Board (IRB), except where necessary to eliminate an immediate hazard(s) to the trial participants. All personnel involved in the 
conduct of this study have completed Human Subjects Protection Training.  
  
  Page 2 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: [ADDRESS_584613]  ............................................................................ 11 
2.1.4  Caregiving  ............................................................................................................................. 11 
2.1.5  Health Disparities in Care of the PWD  .................................................................................. 11 
2.1.6  Interprofessional Education  ................................................................................................... 12 
2.1.7  Existing Relevant Interventions  ............................................................................................. 12 
2.2 NAME [CONTACT_457685]  .............................................. 13 
2.2.1  Preclinical Data ...................................................................................................................... 13 
2.3 CLINICAL DATA TO DATE............................................................................................................... 13 
2.3.1  Development and Implementation of the DSM -H. ................................................................. 13 
2.3.2  Pi[INVESTIGATOR_48124]  ............................................................................................................................ 14 
2.4 RATIONALE  .................................................................................................................................. 14 
2.5 POTENTIAL RISKS & BENEFITS  ...................................................................................................... 14 
2.5.1  Known Potential Risks  ........................................................................................................... 14 
2.5.2  Known Potential Benefits  ...................................................................................................... 15 
3 OBJECTIVES AND PURPO SE ......................................................................................................... 15 
3.1 PRIMARY OBJECTIVES  .................................................................................................................. 15 
3.2 SECONDARY OBJECTIVES  ............................................................................................................. 16 
4 STUDY DESIGN AND ENDPOINTS .................................................................................................. 16 
4.1 DESCRIPTION OF STUDY DESIGN  .................................................................................................. 16 
4.2 STUDY ENDPOINTS ....................................................................................................................... 16 
4.2.1  Primary Study Endpoints  ....................................................................................................... 16 
4.2.2  Secondary Study Endpoints  .................................................................................................. 17 
4.2.3  Exploratory Endpoints  ........................................................................................................... 17 
5 STUDY ENROLLMENT AND WITHDRAWAL FOR PWD- CAREGIVER DYADS  ........................... 17 
5.1 INCLUSION CRITERIA  .................................................................................................................... 17 
5.2 EXCLUSION CRITERIA  ................................................................................................................... 17 
5.3 VULNERABLE SUBJECTS  ............................................................................................................... 17 
5.4 STRATEGIES FOR RECRUITMENT AND RETENTION  .......................................................................... 18 
5.5 DURATION OF STUDY PARTICIPATION  ............................................................................................ 20 
5.6 TOTAL NUMBER OF PARTICIPANTS AND SITES ................................................................................ 20 
5.7 PARTICIPANT WITHDRAWAL OR TERMINATION  ................................................................................ 20 
5.7.1  Reasons for Withdrawal or Termination  ................................................................................ 20 
5.7.2  Handling of Participant Withdrawals or Termination  ............................................................. 20 
5.8 PREMATURE TERMINATION OR SUSPENSION OF STUDY  .................................................................. 20 
6 STUDY QUALITY IMPROV EMENT PROGRAM  ............................................................................... 21 
6.1 STUDY BEHAVIORAL OR SOCIAL QUALITY IMPROVEMENT PROGRAM  ............................................... 21 
  Page 3 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: [ADDRESS_584614] Adherence with Study Quality Improvement Program  .................... 25 
7 STUDY PROCEDURES AND SCHEDULE  ....................................................................................... 25 
7.1 STUDY PROCEDURES /EVALUATIONS  ............................................................................................. [ADDRESS_584615] of Care Study Procedures  ..................................................................................... 26 
7.2 STUDY SCHEDULE  ...................................................................................................................... 266 
7.2.1  Screening  .............................................................................................................................. 26 
7.2.2  Enrollment/Baseline  .............................................................................................................. [ADDRESS_584616]  ...................................................................................... 287 
7.2.6  Withdrawal/Early Termination Visit ...................................................................................... 287 
7.3 CONCOMITANT MEDICATIONS , TREATMENTS , AND PROCEDURES  .................................................. 288 
7.4 JUSTIFICATION FOR SENSITIVE PROCEDURES  .............................................................................. 288 
7.5 PROHIBITED MEDICATIONS , TREATMENTS , AND PROCEDURES  ...................................................... 288 
7.6 PROPHYLACTIC MEDICATIONS , TREATMENTS , AND PROCEDURES  ................................................. 288 
7.7 RESCUE MEDICATIONS , TREATMENTS , AND PROCEDURES  ........................................................... 288 
7.8 PARTICIPANT ACCESS TO STUDY AGENT AT STUDY CLOSURE  ........................................................ 28 
8 ASSESSMENT OF SAFETY  ............................................................................................................. 28 
8.1 SPECIFICATION OF SAFETY PARAMETERS  .................................................................................... 289 
8.1.1  Definition of Adverse Events (AE)  ....................................................................................... 299 
8.1.2  Definition of Serious Adverse Events (SAE)  ....................................................................... 299 
8.1.3  Definition of Unanticipated Problems (UP)  .......................................................................... 309 
8.2 CLASSIFICATION OF AN ADVERSE EVENT  ....................................................................................... 30 
8.2.1  Severity of Event  ................................................................................................................... 30 
8.2.2  Relationship to Study Quality Improvement Program  ........................................................... 30 
8.2.3  Expectedness  ........................................................................................................................ 30 
8.3 TIME PERIOD AND FREQUENCY FOR EVENT ASSESSMENT AND FOLLOW -UP .................................... 30 
8.4 REPORTING PROCEDURES – NOTIFYING THE IRB .......................................................................... 32 
8.4.1  Unanticipated Problem Reporting  ....................................................................................... 321 
8.5 REPORTING PROCEDURES – NOTIFYING THE STUDY SPONSOR  ...................................................... 32 
8.6 REPORTING PROCEDURES – PARTICIPATIN G INVESTIGATORS  ....................................................... [ADDRESS_584617]  ........................................................................................ 33 
9 CLINICAL MONITORING  .................................................................................................................. 34 
10 STATISTICAL CONSIDER ATIONS  .................................................................................................. 34 
10.1 STATISTICAL AND ANALYTICAL PLANS (SAP)  ................................................................................. 34 
10.2 STATISTICAL HYPOTHESES  ........................................................................................................... 34 
10.3 ANALYSIS DATASETS  .................................................................................................................... 35 
10.4 DESCRIPTION OF STATISTICAL METHODS  ...................................................................................... 35 
10.4.1  General Approach  ........................................................................................................... 355 
10.4.2  Safety Analyses  ................................................................................................................ 35 
  Page 4 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 28 APR 2017  10.4.3  Adherence and Retention Analyses  .................................................................................. 35 
10.4.4  Baseline Descriptive Statistics  ........................................................................................ 355 
10.4.5  Planned Interim Analysis  .................................................................................................. 35 
10.4.6  Additional S ub-Group Analyses  ...................................................................................... 365 
10.4.7  Multiple Comparison/Multiplicity  ...................................................................................... 365 
10.4.8  Tabulation of Individual Response Data  ......................................................................... 365 
10.4.9  Exploratory Analyses  ...................................................................................................... 365 
10.5 SAMPLE SIZE ............................................................................................................................. 366 
10.6 MEASURES TO MINIMIZE BIAS ....................................................................................................... 37 
10.6.1  Enrollment/Randomization/Masking Procedures  ............................................................ 376 
10.6.2  Evaluation of Success of Blinding  ..................................................................................... 37 
10.6.3  Breaking the Study Blind/Participant Code  ..................................................................... 376 
11 SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUME NTS ............................... 376 
12 QUALITY ASSURANCE AN D QUALITY CONTROL  ..................................................................... 387 
13 ETHICS/PROTECTION OF  HUMAN SUBJECTS  ............................................................................. [ADDRESS_584618]  ................................................................................................... 388 
13.3 INFORMED CONSENT PROCESS  .................................................................................................. 398 
13.3.1  Consent/Assent and Other Informational Documents Provided to Participants  ............. [ADDRESS_584619] POLICY  .................................................................................................. 42  
18 REFERENCES  ................................................................................................................................. 443 
19 ATTACHMENTS  ................................................................................................................................ 51 
20 SCHEDULE  OF EVENTS  .................................................................................................................. 52 
 
    
 
   
  Page 5 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: [ADDRESS_584620]  Alzheimer’s Disease and Related Disorders  
AE Adverse Event/Adverse Experience  
BPSD  Behavioral and Psychological Symptoms of Dementia  
CFR Code of Federal Regulations  
CG Caregiver  
CRF Case Report Form  
DHHS  Department of Health and Human Services  
DSM -H Dementia Symptom Management at Home Program  
DSMB  Data and Safety Monitoring Board  
FFR Federal Financial Report  
FWA  Federalwide Assurance  
GCP  Good Clinical Practice  
HHC  Home Healthcare  
HIPAA  Health Insurance Portability and Accountability Act  
ICF Informed Consent Form  
ICH International Conference on Harmonisation  
IRB Institutional Review Board  
MOP  Manual of Procedures  
N Number (typi[INVESTIGATOR_33891])  
NIA National Institute on Aging  
NIH National Institutes of Health  
OHRP  Office for Human Research Protections  
NPI-Q Neuropsychiatric Inventory Questionnaire  
OHSR  Office of Human Subjects Research  
PI [INVESTIGATOR_457560]/Serious Adverse Experience  
SCP Standard Clinical Practice  
SOP  Standard Operating Procedure  
US [LOCATION_002]  
 
  Page 6 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: [ADDRESS_584621] of the dementia symptom management at home 
program  
 
Brief Summary  Alzheimer’s Disease and Related Disorders (dementia) poses a significant 
challenge to our public health. While many persons with dementia are cared 
for by [CONTACT_457620], most home healthcare clinicians and agencies are ill prepared to care for this population and therefore have difficulty assisting patients and caregivers in maintaining quality of life leading to adverse patient outcomes, 
increased caregiver stress and burnout, and healthcare utilization. This study 
will therefore utilize a cluster randomized controlled design at 3 study sites to examine the ability of a multi -component evidence-
based practice primary 
palliative care quality improvement program  for home healthcare registered 
nurses , occupational therapi[INVESTIGATOR_457561] .
 
Phase  3 
Objectives  1) Measure the effects of the DSM -H on quality of life  (primary)  and pain and 
BPSD severity (secondary) in the PWD.  
 2) Assess the effects of the DSM- H on quality of life (primary), and physical 
and mental health (secondary) in the informal caregiver of the PWD.  
 3) Assess the effects of the DSM- H on healthcare utili zation in the PWD.  
Primary outcomes are ER visits and hospi[INVESTIGATOR_457562]. Secondary outcomes are outpatient visits and primary care provider contacts.  
 
Methodology  Multi -site cluster randomized controlled trial  of a quality improvement program  
Endpoint  Primary Endpoints: PWD and caregiver QOL. Number of PWD ER visits and 
inpatient admissions  
 
Secondary Endpoints: PWD Pain and severity  of individual BPSD , 
antipsychotic and analgesic use. PWD outpatient visits and primary care provider contacts. Caregiver burden, depression, functional health and well -
being.  
Study Duration  3.75 years  
Participant Duration  60 days  
  Page 7 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 28 APR 2017  Population   
Dyad Population 
Total Sample: 345  Dyads (345 PWD + 345 caregivers)  
Sample a t NYU Site (VNAHG): 207  
Sample a t University of Utah Site (CNS; Central Utah): 86  
Sample at University of Miami Site ( FirstStat; Southern [LOCATION_012]): 52  
Sample Description: PWD and their informal caregiver dyads. PWD must be 
65 or older and informal caregiver 18 or over; English or Spanish speaking; Informal caregiver is defined as spending at least 8 hours per week and had 
an established prior relationship (family, friend, neighbor).  
 
Study Sites   
NYU (lead): 0 clusters  
VNAHG: 12 clusters  
University of Utah: 5 clusters  
University of Miami: 3 clusters  
 
Number of participants   
Dyads: 345 across all sites (see population)  
 
Description of Study Procedure   
The DSM -H is a multi- component quality improvement program that consists 
of clinician training, patient - and family -centered assessment instruments, 
patient -caregiver dyadic centered care plans, a BPSD assessment and 
treatment algorithm, and caregiver teaching sheets.  This study will examine 
outcomes of this quality improvement program.  
 
Reference Therapy  Usual Care  
Key Procedures  None  
Statistical Analysis   
Time trend analysis using repeated measure multivariate mixed effects linear models (PROC MCM in SAS) for all non- utilization outcomes. U tilization 
outcomes will be analyzed through logistic regression for odds of hospi[INVESTIGATOR_457563]. Both will use random effects to measure for 
clustering.  
 
 
  
  Page 8 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 28 APR 2017  
Total 345 Dyads: Subjects receive care through usual home healthcare assignment 
process. Obtain informed consent for both PWD and Caregivers. Screen potential 
subjects by [CONTACT_21198]; document. Perform Visit 1 after consenting.  
Arm 1                  
173 Subjects receiving 
QI program care  
Arm 2              
Control  
172 subjects  
Perform baseline assessments. See Section 19, Schedule of Events Table   
Perform Time 2 assessments (Day 15). See Section 19, Schedule of Events Table  
Perform Time 3 assessments (Day 30). See Section 19, Schedule of Events Table  
 
Final Assessments  
See Section 19, Schedule of Events 
Table  
Prior to  
Enrollment  
Visit 1  
Time 
Point  
Visit 2  
Time 
Point  
Visit 3  
Time 
Point  
Visit 4  
Time 
Point  Schematic of Study Design  
  
 
 
  
  
   
  Page 9 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 28 APR 2017  1 Key R oles 
LEAD SITE: NEW YORK  
 
Principle Investigator  
Abraham Aizer Brody, PhD, RN, GNP -BC, FPCN  
Assistant Professor  
NYU Rory Meyers College of Nursing  
[ADDRESS_584622], Room 504 
[PHONE_9593]  
[EMAIL_8787]  
 
Study S tatistician  
Jason Fletcher, PhD  
Senior Biostatistician  
NYU Rory Meyers College of Nursing  
[ADDRESS_584623], 7th Floor  
[LOCATION_001], NY [ZIP_CODE]  
[PHONE_6407]  
[EMAIL_6030]   
 
EXTERNAL SITE 1: NEW JERSEY   
 
Site PI-N ew Jersey  
Robert Rosati, PhD  
Vice President of Data, Research and Quality 
VNA Health Group  
[ADDRESS_584624], Tuite D1  
Holmdel, NJ [ZIP_CODE]  
[EMAIL_8790]   
 EXTERNAL SITE 2: FLORIDA  
 
Site PI -F
lorida  
James E. Galvin, MD, MS  
University of Miami  
Miller School of Medicine  
[ADDRESS_584625],  
Miami, FL [ZIP_CODE]  
[PHONE_9594]  
[EMAIL_8788]  
 EXTERNAL SITE 3: UTAH  
 
Site PI -U
tah  
Rand Rupper, MD  
Associate [CONTACT_40758] of Utah  
School of Medicine  
C/O George V Whalen VAMC  
VA-Building #2 GRECC 182 
Salt Lake City, UT [ZIP_CODE]  
  Page 10 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 28 APR 2017  [PHONE_9595]  
[EMAIL_8789]  
 
STUDY ADMINISTRATION 
 
Program Officer  
Kristina A McLinden, PhD  
National Institutes of Health/National Institute on Aging 
[ADDRESS_584626], Suite 3E500  
Bethesda, MD [ZIP_CODE]- 9205 
[PHONE_9597]  
 
DSMB Chair  
Malaz Boustani, MD, MPH  
Fairbanks Professor in Aging Research  
Indiana University School of Medicine  
[ADDRESS_584627]  
Indianapolis, IN [ZIP_CODE]  
[PHONE_9598]  
[EMAIL_8791]  
 
 
[ADDRESS_584628] double by [ZIP_CODE]. 
As age is a significant risk factor, this will  lead to a significant increase in patients with various 
causes of dementia including Alzheimer’s disease and related disorders  (ADRD; including Lewy 
body dementia, frontotemporal degeneration, and vascular contribution to cognitive impairment 
and dementia)2.  The In stitute of Medicine 2008 report  sounded  the alarm regarding the lack of 
properly trained clinicians in geriatrics in general3 yet 8 years later the healthcare system is no 
closer to building a workforce to provide high quality care for PWD as highlighted in the National Plan to Address Alzheimer’s
4. The increase in the population of older adults is expected to 
overwhelm the healthcare system; the supply of hospi[INVESTIGATOR_457564]
5.  Thus, these complex patients, many with ADRD, will 
be forced to return to the community in sicker condition than currently seen, after shorter lengths of stay in  the hospi[INVESTIGATOR_307], placing a great strain on HHC  agencies as they will be expected to take on 
care for many of these patients. While an estimated 36% of HHC patients currently have ADRD
6, 
many HHC providers lack even basic training in their care due to a dearth  of validated programs  
and the disseminated nature of the workforce makes developi[INVESTIGATOR_457565] . 
Clinicia ns also have a negative view, and do not recognize that substantial evidence exists 
showing differences in their care needs .7-15,16-[ADDRESS_584629] been recorded of the incidence of pain in the community dwelling PWD, the 
estimated incidence rate in older adults of over 50%[ADDRESS_584630] been found to be ill prepared 
  Page 11 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: [ADDRESS_584631] common and distressing symptoms in the PWD, occurring in over 40% of 
cases32. BPSDs include agitation, depression, delusions, hallucinations, mania, personality changes and 
aggression. BPSDs are associated with weight loss33, functional disability34, caregiver burden and 
burnout35, nursing home admission36, and progression of dementia37. While multiple interventions are 
available for the treatment of BPSD38,39, they are often not appropriately used and certain common 
pharmacologic interventions in particular can cause harmful side effects. Few studies have examined the assessment and treatment of BPSD in the HHC setting. However, multiple studies have examined the effect 
of BPSD in ADRD in the home, particularly as it relates to caregivers, finding that interventions can decrease 
BPSD and improve function, QOL,  and caregiver well -being
40. Other studies have found BPSD plays a 
significant role in caregiver burden and burnout41,42, significantly increase the cost of care43 and familial 
economic burden44. 
 
 Interrelation of Pain  and BPSDs in ADRD  
 
The interrelation of pain and BPSDs in ADRD can have large effects on illness burden and QOL, and many 
patients do not present with just a single symptom. Thus it is important to study their  interrelatedness .45,46 
This is certainly true of pain, depression (one of the major BPSD) and agit ation  (another BPSD), where 
research has found they interact with each other, creating an additive effect when measuring their presence 
and/or severity .47-49  For instance, t he presence of chronic pain in the elderly is known to induce or worsen 
symptoms of depression and agitation;  and depression co- existing with pain is known to worsen the 
intensity of pain and complicate treatment50-52. When all three of these are present, patient function is 
substantially decreased53,54. 
 
 Caregiving  
 
Informal caregivers, including family, friends, neighbors and other acquaintances provide 83% of the care 
to PWD living in the community55, representing 15.9 million people providing 18.1 billion hours of care56. 
Despi[INVESTIGATOR_457566], a recent report from the National Academies of Sciences Engineering 
and Medicine (previously the IOM) finds that caregivers are largely marginalized and ignored as part of the 
healthcare system, and not provided the training or assistance they need in order to successfully care for their charge
57. The primary tasks informal caregivers provide PWD assistance with include activities of daily 
living (ADLs) and instrumental ADLs, medication management and administration, adherence to treatment regimens, interfacing with the medical team, managing BPSDs, finding support services, and managing and hiring paid caregivers
56. These tasks are known to cause informal caregivers stress, burden and 
burnout, and worsen their physical and mental health, including 2- 3 time s greater risk of developi[INVESTIGATOR_457567] (40%). Furthermore, the biologic variable of sex plays an important role in informal caregiving, as caregiving is performed significantly more by [CONTACT_457621] (68%)
58 and they spend 
between 1/3 and double the time providing care than male caregivers56. Additionally, caregivers who are 
older, female, spouses, or live in the same household with the PWD experience higher rates of caregiver burden
58.  
 
 Health Disparities in Care of the PWD  
 
  Page 12 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: [ADDRESS_584632] cited study found that a 2- 3 fold higher risk in African- Americans 
and Hispanics compared to non-H ispanic whites (9.1%, 7.5%, 2.9% respectively in the 65- 74 age cohort 
with even higher disparities as age increases)60. In addition to the higher prevalence rates, research has 
found that African- American and Hispanic caregivers frequently believe cognitive impairment is a normal 
part of aging61 and present for initial diagnosis with higher rates of symptoms62. Overall, Hispanics have 
been found to have higher rates of BPSDs than other groups63. However, both African- Americans and 
Hispanics have lower rates of institutionalization64,65. Therefore caregivers in these populations require 
more community -based support and training to counteract the longer duration of care.  
 
 Interprof essional Education  
 
Brody (PI) and Galvin (Site- PI) performed a systematic review of the literature in interprofessional education 
in ADRD66. They found [ADDRESS_584633]. 
Gitlin, is the Care of Persons with Dementia in their Environment (COPE) Program. This intervention 
focuses on enhancing the PWD’s functional capacity and improving caregiver skills in managing ADRD. It includes [ADDRESS_584634], 
and only 14% of HHC visits are provided by [CONTACT_176796][INVESTIGATOR_11437]80, reducing the ability to implement 
more broadly in the existing HHC service delivery model. Another program the MIND at Home program developed by [CONTACT_457622], and ADRD education and caregiving strategies. It is currently being studied in an NIA funded R01 and CMMI 
demonstration project. This interprofessional program has shown considerable strength in its pi[INVESTIGATOR_457568]
81. However, it did not show caregiver reported 
improvements in BPSD and is also not delivered through HHC. One intervention specifically tailored to HHC by [CONTACT_90023], the CAREPATH program, assists HHC nurses to manage depression in older adults. CAREPATH provides 7 hours of training (4 in- person, 3 via web) to nurses, finding significant improvement in depr essive 
symptoms in persons with higher symptom expression at baseline
82. The primary limitations of this program 
as it relates to this work is that it is solely geared towards depression, it focuses [ADDRESS_584635] been developed to perform palliative care for individuals with cancer and heart failure (ENABLE and ENABLE -
CHF)
83-88. These multi -component nurse- led psycho- educational interventions seek to support the patient 
and their caregiver and ENABLE has shown positive outcomes on QOL, mood, and survival though not utilization, and caregiver stress and burden, while ENABLE- CHF is currently being examined through a 
clinical trial.  However, ENABLE and ENABLE -CHF are not performed through HHC, either utilizing tele -
health, which may not be adequate for PWD given the difficulty with phone assessment in this population, or a clinic model which may be difficult to access for homebound PWD. Lessons learned from these interventions have been used in developi[INVESTIGATOR_457569] -H intervention.  
 
  Page 13 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 28 APR 2017  2.2 Name [CONTACT_457686] -H, is an evidence- based practice quality improvement program that combines training, 
mentorship, workflow enhancements, assessment instruments, a BPSD treatment algorithm, and caregiver 
teaching pamphlets for clinical staff in HHC agencies .  
 
 Preclinical Data  
[IP_ADDRESS]  Under -recognition of symptoms in HC  
Because symptoms such as pain and depression are significant causes of agitation in PWD, [CONTACT_457691]  undertook a 
study
89 that examined the recognition of symptoms in 
advanced illnesses in HHC. Using a 5% sample of nationwide 
OASIS (home health minimum data set collected on every patient) and Medicare data, he examined the rates of symptom 
prevalence in persons with advanced illnesses including advanced dementia post -discharge from an acute care stay. 
He found pain and depression in PWD were significantly under -recognized in HHC (See table 1). Using 
multivariate ordinal logistic regression controlling for age, race, sex, Charlson Score, and rural/urban location, he found that persons with advanced dementia were 2.[ADDRESS_584636] had pain reported 
on the OASIS than the other advanced illnesses he  examined. One highly methodical and well cited 
nationwide study found that late life pain incidence rate is 46% the month prior to death; the majority of this 
pain coming from arthritis; with no difference by [CONTACT_457623]
90.  
 
Thus the investigators  would not expect significantly different rates across these disease categories, and 
the rates of pain in advanced dementia are likely significantly under -recognized. Similarly, using multivariate 
logistic regression with the same control variables, persons with advanced dementia were 1.[ADDRESS_584637]. Brody’s National Palliative Care Research Center Career Development Award, [CONTACT_457691] and 
[CONTACT_457690] (Mentor)  developed the DSM -H. The development utilized the NIH ORBIT Model for Behavioral 
Intervention Development93 and later on the Structural Model for Caregiving Stress94. The DSM- H focuses  
on assisting skilled HHC clinicians to identify a nd managing behavioral symptoms assoc iated with 
dementia, and work  as a team with the primary care provider and informal caregiver . In this initial trial, t wo 
registered nurse, physical therapi[INVESTIGATOR_541] , and occupational therapi[INVESTIGATOR_457570] (6 total educators) at the study 
site were trained as “champi[INVESTIGATOR_5458]” and received 14 hours of in- person , case based  interprofessional 
instruction over two days in dementia care; the remaining [ADDRESS_584638]. The survey  incorporates three well -
validated instruments for assessing clinician knowledge and attitudes regarding pain95, depression96 and 
agitation97 in PWD, with an investigator -derived set of four questions about confidence in treating each of 
these symptoms in PWD .  The survey  had an excellent internal consistency in HHC clinicians (Cronbach 

  Page 14 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 28 APR 2017  alpha=.94) and took  an average of [ADDRESS_584639] improvement in knowledge (20.9%) 
and confidence (27.1%) in managing BPSD from baseline with additional gains in knowledge (14.8%) and 
confidence (36.1%) in managing depression and knowledge (5.9%) and confidence (26.5%) in managing 
pain (p<.0001)25. Additionally, on the post -test evaluation, 97% of RNs and 100% of PTs and OTs stated 
the education was highly applicable to their work setting and helped them care for pat ients. Therefore, the 
DSM -H is an evidence- based practice integrated multi -component intervention that has shown 
improved clinician knowledge, attitudes and confidence in treating PWD.  
 
 Pi[INVESTIGATOR_457571]- H, [CONTACT_457691] refined the clinical education programs to 
reduce pharmacology content and increase content on recognition of dementia and non- pharmacologic 
management and working with caregivers. Drs. Brody and Galvin performed a site controlled trial of the 
DSM-H at [ADDRESS_584640] 60- day re -certification or discharge from HHC. Overall, during the study period 
158 PWD were seen by [CONTACT_457624] 174  by [CONTACT_457625]. Overall, patients were older, 
primarily spoke English or Spanish, were either Medicare or dual Medicare/Medicaid insured, and were 
admitted either from home or the acute care setting (See Appendix A). There were fewer black/Afric an 
American participants in the control, the only clinically significant difference (34.2% vs 51.7%; p=.0002). Overall, we found in multivariate analysis that recognition of pain, depression, and behavioral symptoms, were all clinically and statistically significantly higher in the intervention group, and there were significantly increased odds of analgesics use (OR=2.01; p<.05) and decreased odds of antipsychotic use (OR -0.53; 
p<.05) in the intervention cohort
98. These results show the DSM -H has the potential to be im prove 
patient care and the QOL of PWD receiving HHC.  
 
2.[ADDRESS_584641] the efficacy of the DSM- H in a behavioral phase III cluster 
randomized controlled trial.  
2.5 Potential Risks & Benefits 
 Known Potential Risks  
 
The performance improvement program  itself is inherently not risky ( minimal risk ) as it is an 
implementation of evidence -based practices. The primary risk to patients and caregivers in this study is 
the emotional nature of the questions from study data collection, which is solely an immediate risk.  While 
the measures being used are all evidence based and thoroughly tested, they cover issues such as 
increased severity of dementia, depression, agitation, burden and quality of life that could create emotional problems. This will be minimized by [CONTACT_67940] a thorough training plan and manual for the 
research assistant performing the assessments, laying out responses that should be provided to sensitive 
questions, ensuring that the assessment instruments are uniformly administered, and methods and contact [CONTACT_457626]. We are 
  Page 15 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: [ADDRESS_584642], potential types of questions, and the voluntary nature of the 
study. The second risk is loss of confidentiality. We minimize the risk by [CONTACT_457627] a secured fashion (see section 11 ). This vulnerable population is included as the focus of the research is in 
improving the quality of care they receive.  
 
A
s the potential risks are minimal and there are potential direct benefits to subjects in the performance 
improvement cohort, including improved PWD and caregiver QOL and symptom management, and 
reduced utilization, the potential benefits of this study far outweigh the minimal risks to this study. The value in this study is that if efficacy is found, the intervention can be created into a product that is disseminated to some of the over 12,000 active HHC agencies in the country to improve the quality of 
care in these settings and QOL for hundreds of thousands of PWD -informal caregiver dyads.  
 Known Potential Benefits 
 
Potential benefits to patients in the intervention includes improved quality of care and quality of life, including 
reduction in pain and BPSD, and reduced healthcare utilization, which could lead to lower out of pocket costs. For caregivers receiving care from care teams who are part of the performance improvement program , potential benefits include reduced depression, burden, and improved physical and mental health. 
These hypothesized benefits are based on our preliminary data found in section 2.3.2.  
3 Objectives and Purpose  
3.1 Primary Objective s 
 Aim 1: Measure the effects of the DSM -H on quality of life and symptom severity in the PWD.  
H1: PWD cared for by a HHC team utilizing the DSM- H performance improvement program will show 
reduced symptoms and improved ratings of pain, BPSD, and caregiver -rated QOL at the end of the first 
60-day HHC certification period compared to the control (usual care) group.  
 
The primary outcome of Aim 1 is caregiver rated QOL . It will be measured using the Quality of 
Life-Alzheimer’s Disease99.  
 Aim 2: Assess the effects of the DSM -H on quality of life, and physical and mental health in the 
informal caregiver of the PWD.  
H2: Informal caregivers of PWD cared for by a HHC team utilizing the DSM- H performance improvement 
program will show reduced ratings of burden, and depression, and improved functional health and well -
being at the end of the first 60- day HHC certification period compared to the control (usual care) group.  
 The primary outcome of A im 2 is informal caregiver QOL. It will be measured using the Caregiver -Targeted 
Quality of Life Measure
100. 
 Aim 3: Assess the effects of the DSM -H on healthcare utilization in the PWD.   
H3: PWD cared for by a HHC team utilizing the DSM -H performance improvement program will show a 
reduction in emergency room visits and hospi[INVESTIGATOR_457572] (usual care) group, and a greater number of outpatient visits.  
 The primary outcomes to be measured are the number of emergency room visits and hospi[INVESTIGATOR_457573] 30 and 60 days. It will be measured through interviews with the informal caregiver using the Resource Utilization Inventory
101. 
  Page 16 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 28 APR 2017  3.2 Secondary Objectives 
 
The secondary objectives of Aim 1 are  t o assess the effects of the performance improvement program on 
pain and individual BPSD s in the PWD, and the use of antipsychotic and analgesic. They will be measured 
at all four time points (0, 15, 30, and 60 days). BPSD will be measured using the NPI -Q102. The type of pain 
assessment administered to the PWD will depend on their level of cognitive impairment.  The level of 
impairment will be determined by [CONTACT_457628] (QDRS) score. The PWD who obtains 
a score of < 12 will receive the  Bri ef Pain Inventory Short Form103 and those whose score ≧[ADDRESS_584643] study data in order to maintain the integrity of the blinding. The 
potential for contamination between care teams randomized to receive the DSM -H performance 
improvement program and those who will provide usual care is minimal due to the nature of HHC clinician workflow where minimal time is spent in the office, and different care teams do not generally congregate 
with each other except during highly structured staff meetings. The investigators  considered randomizing 
by [CONTACT_457629]; however, given the lack  of contamination found in prior studies of 
the DSM- H combined with differences in care provision at other sites/locations and the need for a large 
number of clusters when using this methodology, the investigators  felt this method was the most likely to 
provide valid and reliable results. It is not possible to randomize by [CONTACT_457630] a given geographic region. Patients in the performance improvement group will 
receive care from a care team who has received the DSM -H performance improvement program, and those 
in the control will receive usual care from a care team who has not received the performance improvement program . Patients at the study sites are only cared for by [CONTACT_457631] a mixture of care teams.  
4.2 Study Endpoints  
 Primary Study Endpoints 
 
Given that this is a dyadic, implementation science intervention, it is not appropriate to look at a single 
primary endpoint. There are therefore 3 primary endpoints that will be examined in this study. For the Aim 1 primary endpoint, PWD QOL, a 0.5 SD difference between the baseline and 60 day visit would be clinically meaningful based on prior studies
40 and therefore considered a positive outcome. For the Aim 2 primary 
  Page 17 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 28 APR 2017  endpoint, informal caregiver QOL, given its rate of variability and floor and ceiling effects, a 0.5 SD 
difference between the baseline and 60 day visit would be clinically meaningful and therefore considered a 
positive outcome100. For the Aim 3 primary endpoint, a 10% reduction in readmissions and ER visits at [ADDRESS_584644] caregivers and can increase burde n due to the coordination that is required of caregivers
107. 
 Exploratory Endpoints 
 In this study we will explore both sub- group analysis by [CONTACT_547], race/ethnicity, health literacy, and high 
and low symptom individuals.  
5 Study Enrollment  and Withdrawal  for PWD-Caregiver Dy ads 
5.1 Inclusion Criteria  
 
1. PWD over the age of 65  
2. Admitted to one of the three HHC agencies  
3. The patient and family caregiver speak English and/or Spanish.  
4. The informal caregiver is ≥18 years of age and manages the PWD’s care for  at least 8 hours per 
week.  
5. Patients who score ≥6 on the Quick Dementia Rating Scale (at least mild impairment).  
6. PWD and the caregiver have internet connection.  
5.[ADDRESS_584645] a capacity status change in such a short period of time (60 days). Should the person with dementia subject become distressed from participating in the study, they will be withdrawn from the study.  
  Page 18 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 28 APR 2017   
5.4 Strategies for Recruitment and Retention  
 
A centralized referral  system will be  customized to each of the three HHC agency's organizational structure 
and workflow . Each agency  will determine which staff will be designated as the point of contact (POC) to 
submit patient referrals to the DSM- H research team.  The method of referral will differ among agencies 
based on each organizational workflow. Each HHC agency accepts new  referrals for patient admission 
through an intake process prior to the patient meeting with a nurse to initiate start of care (SOC).  The nurse 
who completes the patient’s admission visit, administers an OASIS assessment and OASIS cognitive 
screen or  administer s a mini -cog test108 for the patient’s SOC  report .  The HHC agency’s POC  will review  
patient  information obtained through intake and the SOC report .  New admissions who are aged [ADDRESS_584646] director will upload the referral information directly into redcap, 
the study log.  
 
 Each agency has determined how t heir c entralized referral  system will be facilitated as noted below:   
 New Jersey site (VNAHG)  there will be a single point of contact [CONTACT_457632]/innovation group who 
will run twice -daily reports of persons with dementia newly admitted to the agency who live in a private 
residence. R eports are based on the nurse’s SOC report submitted at the end of the day.   
 Utah site (CNS)  there will be a single point of contact [CONTACT_457633] a daily report 
of persons with dementia newly admitted to the agency who live in a private residence. The report will 
be based on the nurse’s SOC report and made available to designated study staff or care team office  
referral specialist for referral submission.  
  [LOCATION_012] site (FIRSTAT ) there will be a single point of contact [CONTACT_457633] a daily 
report of persons with dementia newly admitted to the agency who live in a private residence. The 
report  will be based on the nurse’s SOC report and made available to designated study staff or care 
team office referral specialist for referral submission.  
  
Per
sons with dementia who are newly admitted into each HHC agency  will be included in an "opt -out" 
referral process. Admission packets , provided to those who have been identified as meeting DSM- H 
inclusion criteria,  will include a  DSM -H research study information card. The DSM -H info -card provides an 
overview of the research study, the duration of participation, contact [CONTACT_457634], as well as, ways in which the patient and caregiver can opt out from being contact[INVESTIGATOR_530].   
 
In follow up to the patient referrals received by [CONTACT_435728],  the research team  will contact [CONTACT_264029]/or caregiver to introduce them to the research study and to screen the referral for subject eligibility. To 
determine if the PWD’s level of cognitive impairment meets eligibility for inclusion, the QDRS is adminis tered to the caregiver who will rate the PWD’s symptoms and behaviors. A PWD who scores > 6 on 
the QDRS will meet eligibility for study inclusion as this score indicates mild impairment, similar to a score 
of <23 on the MMSE. The research team will also inquire about whether the caregiver makes decisions on 
behalf of the PWD, or if there is a legally authorized representative who acts on the PWD’s behalf.  If the PWD has a LAR, then that representative’s contact [CONTACT_457635].  A virtual visit is scheduled for both the PWD and caregiver within 3 business days of the PWD’s admission date so that additional information about the study can be provided and informed consent can be conducted. Weekend days and U.S. recognized business holidays are not counted as a 
business day. The PWD must have the capacity to consent in order to sign their consent form.  
 
C
apacity to consent will be determined using a standardized 3- question approach109 performed by [CONTACT_457636] . These individuals will receive training from the PI [INVESTIGATOR_457574]. In these simulations, one will have capacity and the other will not. They must correctly assess both simulations prior to being allowed 
  Page 19 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 28 APR 2017  to perform the consent process. This standardized approach has been shown to be valid for use by [CONTACT_457637]. The three questions that will be asked after reviewing the study consent form are: 1) 
What is the purpose of the study, 2) What are the risks, and 3) What are the benefits. If the initial response 
is vague or suggests misunderstanding, the interviewer re- explains or clarifies the question without 
redisclosing information about the study. The interviewer scores the answer to each question as as either 0 (incapable) 1 (questionable) or 2 (capable).  Definitions of these are as follows: “2-point score reflects 
clear understanding of the disclosed material, a 0- point score reflects definite misunderstanding of the 
disclosed material, and a 1- point score reflects either partial but less than fully adequate understanding or, 
if this persists even after prompting for clarification, an uncertain level of participant understanding.”  The 
score is then totaled and a score of less than [ADDRESS_584647] capacity. This method has a high 
level of sensitivity and specificity and is more accurate than using other methods including the mini -mental 
status exam (MMSE).  
 This standardized process is accurate and objective. There is limited conflict of interest in having the study 
personnel perform this assessment as opposed to an independent assessor as the study could still recruit 
dyads through surrogate consent should a subject not have capacity, and the  patient flow at the participating 
HHC agencies far exceeds the needs of this study thus limiting pressure to enroll on the part of the study staff.  
 In instances where a PWD does not have the capacity  to consent, their enrollment will be contingent upon 
consent being provided by [CONTACT_457638] a legal surrogate as determined by [CONTACT_457639].  Further, once consent on the behalf of the PWD has been acquired, the PWD will be asked to assent verbally and if able, by [INVESTIGATOR_59844]. If the PWD provides verbal assent but is unable to provide their signature [CONTACT_457687] (cognitive/physical), the researcher will note on the assent form that the PWD provided verbal assent but was unable to sign.  
 The legal surrogate will be verified by [CONTACT_457640]. Should they not have written documentation of being an appointed surrogate, the law of the state of residence will determine the priority order for determining the surrogate, which is as follows:  
 [LOCATION_012]:         spouse, adult child, parent, adult sibling, close friend  
New Jersey: spouse, adult child, parent, sibling, close friend Utah:             spouse, adult child, parent, sibling, grandchild, grandparent, individual who is healthcare proxy  
 Because PWD in HHC are primarily homebound, tend to receive HHC for at least [ADDRESS_584648] information for the PWD, caregiver, 
and where applicable proxy, will schedule the follow -up visits at the initial visit, email  or text the vi sit 
schedule to the caregiver (based on caregiver preference; no PHI or PII included, see templates), and call 4 days and 1 day prior to each follow -up appointment to confirm and/or reschedule.  
 
The greatest risks to retention are re- hospi[INVESTIGATOR_457575], either for short -term post -acute 
rehabilitation after a re- hospi[INVESTIGATOR_457576]- term institutionalization for ADRD.  Subjects are not required 
to attend the intermediate and final visits together. Efforts to accommodate the subjects’  schedules will be 
considered in data collection. Phone interviews with the PWD and caregiver to collect participant survey 
data will occur for all time points. If both subjects are unavailable to complete an intermediate visit, the visit will be recorded as missed. To maintain subject retention, subjects will be terminated from the study only if 
the caregiver, as respondent, does not complete visit four.  
 
Dyads will be enrolled starting in month 6 of year 1 and continuing through month 9 of year 4 (3 years, 3 months). Follow -up will continue through Month 2 of year 5. The investigators therefore anticipate recruiting 
9 new dyads per month at all sites throughout the 4 years, with 5- 6 through the VNA Health Group, 2- 3 at 
the University of Utah and 1- 2 at Uni versity  of Miami . 
 
  Page 20 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 28 APR 2017  Given that this research study is of short duration (60 days) there is no reasonable expectation 
that there to be a change in capacity during the time period of the study and will therefore not 
monitor for capacity beyond the initial vis it. 
5.[ADDRESS_584649] 65 days from recruitment to completion. The total duration is intended to be 60 
days, however, for the interim study visits (visits 2 and 3) we will allow the visit +/ - 3 days to allow for PWD -
caregiver schedule, and at visit 4, up to +[ADDRESS_584650].  
5.6 Total Number of Participants and Sites  
Recruitment will end when approximately 345 dyads (345 PWD and 345 caregivers) are enrolled. It is 
expected that approximately  345 dyads will be enrolled in order to produce 300 evaluable dyads . 
 Sample at VNAHG Site: 207 dyads (207 PWD, 207 caregivers) enrolled, with expectation of 180 complete dyad cases (180 PWD, 180 caregivers).  
Sample at University of Utah Site: 86 dyads enrolled (86 PWD, 86 caregivers) with expectation of 75 
complete dyad cases (75 PWD, 75 caregivers).  
 
Sample at University of Miami Site: 52 dyads enrolled (52 PWD, 52 caregivers) with expectation of 45 complete dyad cases (45 PWD, 45 caregivers).  
 
5.[ADDRESS_584651]. An investigator may terminate participation in the study if:  
• The participant meets an exclusion criterion (either newly developed or not previously 
recognized) that precludes further study participation  
• The study team is unable to maintain or appropriately reschedule study appointments.  
 Handling of Participant Withdrawals or Termination  
Given the minimal risk nature of this study, individuals who chose to withdraw from the study will not 
continue to be followed in any form. We  have factored in a 15% study non- completion rate and anticipate 
recruiting 345 dyads to meet the 300 dyads required study participants.   Subjects will not be disenrolled based on data related issues.  If subjects are unable to attend intermediate visits (Visit 2 and/or 3), those visits will be counted as missed. If the caregiver does not complete visit four, both subjects will be  
terminated from the study.   
 
5.8 Premature Termination or Suspension of Study  
 
This study may be temporarily suspended or prematurely terminated if there is sufficient reasonable cause. Written notification, documenting the reason for study suspension or termination, will be provided by [CONTACT_457641], the NIA program officer, and t he DSMB. If the 
study is prematurely terminated or suspended, the PI [INVESTIGATOR_118627](s) for the termination or suspension.  
Circumstances that may warrant termination or suspension include, but are not limited to:  
• Determination of unexpected, significant, or unacceptable risk to participants  
  Page 21 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 28 APR 2017  • Insufficient compliance to protocol requirements  
• Data that are not sufficiently complete and/or evaluable 
• Determination of futility  
• DSMB or NIH halts study for any other reasons  not listed above.  
 
Study may resume once concerns about safety, protocol compliance, data quality are addressed and 
satisfy the NIH, IRB and DSMB.  
 
6 Study Quality Improvement Program  
6.1 Study Behavioral or Social Quality Improvement Program  
 
The DSM- H is a qu ality improvement program that has been tested in several HHC agencies in [LOCATION_001]. 
It is a multi -modal quality improvement program for improving the quality of care provided to PWD -informal 
caregiver dyads through HHC. All training was initially created through participatory research with an 
interprofessional team of clinicians, and then refined through feedback from clinicians who completed the 
training. It has been culturally tailored for use in diverse settings and tested with multiple minority communit ies in [LOCATION_001], including multiple Hispanic groups and African- Americans and Caribbean blacks. 
Components of the intervention are described in detail below and in Figure 2 (see below).  The DSM- H 
quality improvement program presented in this section is not  in and of itself a study intervention. We are 
solely in this study measuring the outcomes of the quality improvement program, however include the components of the program here so it is easier to understand the research protocol around the study of outcomes.  
 
 Champi[INVESTIGATOR_457577]- person didactic content, case studies, and 
role-playing simulation cases. There are three core components of the champi[INVESTIGATOR_45371], the Leadership 
Training Program, training on care of the PWD and their caregiver, and communication both within the team 
and with the PWD -caregiver dyad in a patient -centered fashion. The leadership content is modeled after 
the Hartford Institute for Geriatric Nursing’s highly successful NICHE program leadership training program, which provides implementation training on geriatric principles for acute care hospi[INVESTIGATOR_457578] [ADDRESS_584652] specific content mirrors non- champi[INVESTIGATOR_45371] (see below) in 
more depth, and includes assessing patients for ADRD, assessing and managing pain and BPSD in PWD 
using the safest, least restrictive, non- pharmacologic and pharmacologic treatments , caring for individuals 
who are either resistant or unable to complete care due to ADRD, working with caregivers who work with 
PWD. It also covers additional topi[INVESTIGATOR_457579] , 
utilization of advanced directives, and transitioning to hospi[INVESTIGATOR_6125]. The third component, dyadic person-centered team based care is based on three well validated programs, AHRQ TeamSTEPPS
[ADDRESS_584653] problematic behaviors. 
Champi[INVESTIGATOR_457580], 
resources/mentors and ensures quality improvement program fidelity in implementation throughout the study.  
 
  Page 22 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 28 APR 2017   
 
 
 Non-champi[INVESTIGATOR_457581]- champi[INVESTIGATOR_457582] (registered nurses, physical therapi[INVESTIGATOR_11437], occupational therapi[INVESTIGATOR_11437]) will 
undergo five hours of online interactive learning modules which are each one hour in length and will be 
available over two months.  This is done based on our prior experience to ensure completion of the modules 
without over -burdening staff or requiring them to take a lower patient workload, which could have significant 
fiscal impact on the agency and thus reduce the likelihood of involvement.  The content of the modules largely mimics the larger champi[INVESTIGATOR_457583], focusing more on assessment/recognition of 
conditions. The five 1- hour modules are: 1. Defining and distinguishing types of ADRD, assessing patients 
for ADRD; Basic non- pharmacologic and pharmacologic treatments  for decline in PWD; Working with PWD 
to complete care tasks (e.g. registered nurse care, physical or occupational therapy care, instructing 
caregivers); 2. Assessing PWD for pain; non- pharmacologic and pharmacologic strategies for treating pain 
in the PWD; 3. Understanding, assessing and recognizing BPSD; 4. Non- pharmacologic and 
pharmacologic treatments for managing BPSD; 5. Dyadic  person- centered team based care concepts 
derived from AHRQ TeamSTEPPS, SBAR, and Antecedent -Behavior Consequence method of problem 
solving.  
 Validated Instruments  
 
Validated assessment instruments are integrated into the workflow of HHC clinicians who are part of the 
teams receiving the DSM- H performance improvement program to allow for better assessment of cognition, 
pain, and BPSD and are validated in both English and Spanish. These tools are reviewed in the education 
of both champi[INVESTIGATOR_457584] -champi[INVESTIGATOR_5458]. Instruments included are the mini- cog108 for cognition, NPI -Q102 for 
BPSD, the Cornell Scale for Depression in Dementia114 in moderate/severe dementia, the Geriatric 
Depression Scale- Short Form115 in mild dementia for depression, the PAINAD116 and BPI [INVESTIGATOR_457585]/severe dementia, and the caregiver strain index117. These instruments are not part 
of research and are for clinical use by [CONTACT_457642].  
 Interprofessional care plans  
 

  Page 23 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 28 APR 2017  Interprofessional care plans that guide overall care for PWD, with modules specific to pain and BPSD, are 
available to clinicians in the performance improvement  care teams.  These care plans provide algorithms 
to guide clinicians when dealing with specific issues in older adults and are consistent with the information taught in the online and champi[INVESTIGATOR_457586]. For instance, in PWD with sleep disturbance, care plans describe evidence based practices around implementing appropriate sleep hygiene and habits, stimulating patients during the day through activities, and environmental changes to improve sleep quality. Each plan is associated with tailored caregiver and/or patient education pamphlets  that are written in both 
English and Spanish (generalized Latin American Spanish) that can be reviewed on site electronically and 
then mailed or brought to the next v isit. 
 Administration of Quality Improvement Program  
The administration will be delivered by [CONTACT_457643]. The number of sessions may be variable as HHC teams see patients a variable number of times depending on the 
condition they are seeing the patient for and operational needs of the HHC agency.  
 Procedures for Training Quality Improvement Teams and Monitoring Fidelity  
Because there are multiple care teams receiving the performance improvement program , and we need to 
understand how well the program is implemented in order to assess the research outcomes, we will measure fidelity of implementation (e.g. clinician exposure to the performance improvement program ) as 
well as differences across control and performance im provement teams through assessing registered 
nurse, physical and occupational therapi[INVESTIGATOR_457587], attitudes and confidence using Drs. Brody and Galvin’s previously validated dementia symptom knowledge and attitudes survey at baseline, 6 months, 
and annually thereafter
25, comparing differences across intervention and control teams for contamination, 
and through measuring the number of care plans initiated, caregiver teaching sheets provided to caregivers, and assessment instruments used at each site and in each care team throughout the trial.  
 As the survey is primarily being collected for research purposes and not quality improvement purposes, w e 
will consent clinicians who participate in the completion of the knowledge surveys . Completion of the 
training and clinical performance however will be seen as an operational, quality improvement requirement of the agencies, similar to Drs. Brody and Galvin’s prior successfully IRB approved studies. Champi[INVESTIGATOR_457588] a monthly conference call with the investigators and spend [ADDRESS_584654] assessments, as well as for performance improvement on a quarterly basis.  
 
[IP_ADDRESS]  Clinician Proced ures for Fidelity Monitoring  
[IP_ADDRESS].[ADDRESS_584655] that the overall population will be 85% female, 64% Caucasian non- Hispanic, 
14% black non- Hispanic, 21% Caucasian Hispanic, and 1% Asian. A total of 300 clinicians will be 
recruited and perform fidelity monitoring through an online survey at the NYU study site.  
 
  Page 24 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 28 APR 2017  [IP_ADDRESS].2  Recruitment and retention strategies  of Clinician Fidelity Monitoring   
[IP_ADDRESS].2.1  Recruitment Strategy of Clinician Fidelity Monitoring  
The PI [INVESTIGATOR_1238]/or site- PI [INVESTIGATOR_457589] a 
site visit at a regularly sche duled staff meeting to explain the purpose of the trial. This will be followed by 
[CONTACT_457644] -staff email regarding the study from the agency CEO or delegate. We will also receive a list of eligible 
staff from the HHC agency. We will send several emails requesting participation in the study. For those 
individuals who do not respond to email, we will also perform a recruitment phone call to their agency cell phone. We will seek a waiver of documentation of consent and provide a statement at the beginning of the Qualtrics survey using a standardized statement approved by [CONTACT_457645].  
[IP_ADDRESS].2.[ADDRESS_584656] shown high recruitment and retention rates (92- 100%) using these methods.  
[IP_ADDRESS].2.3  Criteria for inclusion/exclusion of Clinician Fidelity Monitoring  
All English speaking registered nurses, physical therapi[INVESTIGATOR_457590] 18 years of 
age will be eligible. This includes both bedside clinicians as well as the managers, team leads, and educators who support them.  
[IP_ADDRESS].2.[ADDRESS_584657] job actions performed secondary to fidelity monitoring by [CONTACT_41314].  
[IP_ADDRESS].2.[ADDRESS_584658] use your NYU campus login credential and starting September 1, 2017, multifactor authentication, to access through a secure portal. Once data is collected and being prepared for analysis, it will be downloaded into a NYU Box folder owned by [CONTACT_978] [INVESTIGATOR_457591]. NYU Box is controlled by [CONTACT_457646]. It is HIPAA compliant and approved by [CONTACT_457647]. Data will be collected through the Qualtrics survey by [CONTACT_457648] a personal 
or agency owned device. Data collected by [CONTACT_457649].  
[IP_ADDRESS].2.6  Potential Benefits for Clinician Fidelity Monitoring  
There are no inherent benefits associated with performing the DSKA as part of participation in this study.  
[IP_ADDRESS].2.7  Source of Materials for Fidelity Review  
The DSKA will be collected at baseline, six months, and annually thereafter. It takes approximately 20 
minutes to complete. It includes baseline demographics (first survey only for an individual) and [ADDRESS_584659] four years in intervention and control settings and 
  Page 25 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: [ADDRESS_584660] assessments.  
[IP_ADDRESS].2.8  Importance of Knowledge to be Gained in Fidelity Monitoring  
This will help the investigators to understand the fidelity of implementation of the quality improvement 
program as well as whether  there are environmental changes across the agency.  
[IP_ADDRESS].2.[ADDRESS_584661] Adherence with Study Quality Improvement Program  
Subjects will not be monitored for any specific adherence to care interventions suggested by [CONTACT_457650] a service delivery, evidence based practice intervention.  
7 Study Procedures  and Schedule  
7.1 Study Procedures/Evaluations  
 Study Specific Procedures 
All data will be collected virtually via telephone and through internet capabilities. The following 
questionnaires will be collected by [CONTACT_457651]:   
 
• Quick Dementia Rating Scale (QDRS): Is a 10- item tool that measures cognitive impairment based on 
the severity of dementia.  
• Neuropsychiatric Inventory Questionnaire ( NPI-Q): Is a 13- item tool that measures caregiver 
perceptions of dementia BPSD  presence and severity . 
• Quality of Life in Alzheimer’s Disease (QOL- AD): Is a 13- item tool that measures caregiver perceptions 
of quality of life in the PWD  
• PAINAD: Is a pain assessment tool for use in persons with moderate to severe dementia who cannot 
provide reliable report . 
• Brief Pain Inventory Short Form (BPI) is a 9- item tool that measures pain location, severity and intensity . 
• FAM -CAM: Is an 11- item tool that is an informant -based assessment of delirium.  
• Medication Record and use: We will create a list of medications the PWD is taking as well as the 
frequency of administration of any PRN medications taken, including any OTC or herbal supplements. 
The primary reason for collecting this data is to examine analgesic and antipsychotic use.  
• Caregiver Targeted Quality of Life Tool (CGQOL): Is an 80- item tool with 10 domains for measuring the 
quality of life of the caregiver of the PWD.  
• Public Health Questionnaire 9 (PHQ -9): Is a 9- item tool that measures depressive symptoms.  
• Zarit Burden Inventory: Is a 22 -item tool that measures caregiver burden.  
• SF-12: The SF -12 is a 12- item tool that measures functional health and well -being.  
• ADLs and IADLS: Are 12 items that measure functional status  as part of the QOL -AD. 
• Charlson Comorbidity Index: Is a reliable and valid comorbidity assessment tool.    
• The Short Assessment of Health Literacy (SAHL): Is an 18- item test designed to examine health literacy 
levels  
• Other non- instrumented questions that will be asked include sociodemographics (DOB, sex, hi ghest 
education level attained, race, e thnicity, primary language, religion, marital status, household members, 
number type and frequency of unpaid and pain caregivers, and primary care provider name [CONTACT_3669] 
[CONTACT_457652] . 
  Page 26 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 28 APR 2017  • Information obtained from the chart includes: Number of visits by [CONTACT_457653], 
comorbidities.  
• Resource Utilization Inventory: Is a 13- item tool to measure healthcare resource utilization.  
• HHCAHPS: Is a [ADDRESS_584662] this on all patients, they are not always successfully able to do so and we will therefore measure independently to avoid missing data.  
• Investigator derived questions asking if their caregiving practices have shifted due to the COVID -[ADDRESS_584663] “not opted out” from being contact[CONTACT_457654]’s referral. The research team will inquire on their interest in learning about the study and whether they may be interested in participating prior to screening for eligibility. Screening will be initiated in the first contact [CONTACT_457655]/exclusion criteria.
 To 
determine if the PWD’s level of cognitive impairment meets eligibility for inclusion, the QDRS will be 
administered to the caregiver who will rate the PWD’s symptoms and behaviors. Caregivers will be 
provided with a copy of the QDRS assessment form for their review.  A research team member will 
complete the form with the caregiver over the phone. A score will be tallied to determine the PWD’s level of cognitive impairment. A PWD who obtains a s core >[ADDRESS_584664] will be completed within 3 business days from the PWD’s start of 
care date.  In circumstances where subjects who provide their consent verbally yet lack the ability to 
electronically sign the informed consent document  due to lack of internet access or computer literacy , we 
will mail them a copy of the consent form to review and confirm at visit 2 their intent to continue 
participation  in order to ensure equity in participation. Providing consent/assent has been obtained, the 
remainder of the virtual visit will be utilized for subject data  collection. Further, the QDRS score will 
determine which assessments are administered to the PWD.   
 
 Enrollment/Baseline  
The enrollment and baseline visit (if eligible and enrolled) will occur on the same day.  
 
Enrollment/Baseline Visit  
Visit 1, (Day 0/1) the following surveys will be collected during visit one. Surveys administered to the 
PWD are indicated by [CONTACT_457656] s core:  
 
o PAINAD (if QDRS >12) 
o FAM -CAM  
o B rief Pain Inventory Short Form (BPI ; if QDRS <12). 
o Quality of Life in Alzheimer’s Disease (QOL- AD) (if QDRS <12) 
o Neuropsychiatric Inventory Questionnaire (NPI -Q) 
o Caregiver Targeted Quality of Life Tool (CGQOL):  
o Public Health Questionnaire 9 (PHQ -9) 
o Zarit Burden Inventory  
o SF-12 
o Charlson Comorbidity  
  Page 27 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 28 APR 2017  o Katz ADLs and Lawton IADLS (through the QOL- AD) 
o The Short Assessment of Health Literacy (SAHL)  
o Other non- instrumented questions that will be asked include sociodemographics ( DOB, sex, 
highest education level attained, race, ethnicity, primary language, religion, marital status, 
household members, number type and frequency of unpaid and pain caregivers , medication 
record and use, primary care provider name [CONTACT_3669] [CONTACT_457652] . 
o Information obtained from the chart includes: Number of visits by [CONTACT_457657], comorbidities , COVID -19 questions . 
 
 Intermediate Visits:   
  
Visit 2 (Day 15+/ -3)  
The following surveys will be administered for visit two:    
Surveys administered to the PWD are indicated by  [CONTACT_457658]:  
 
o BPI (If QDRS<12)  
o PAINAD (If QDRS >12)  
o FAM -CAM  
o NPI-Q   
o Katz ADLs and Lawton iADLs  (through the QOL- AD)  
o Non- instrumented: Medication Record and Usage,  AE and SAE  
 
Visit 3 (Day 30+/-3)  
The following surveys will be administered for visit three:  
Surveys administered to the PWD are indicated by [CONTACT_457659] : 
 
o PAINAD (If QDRS >12)  
o FAM -CAM  
o BPI ( If QDRS <12) 
o NPI--Q 
o Katz ADLs and Lawton iADLs  (through the QOL- AD)  
o Resource Utilization Inventory  
o Non- instrumented: Medication Record and Usage,  Resource Utilization Inventory , AE and 
SAE, COVID -19 questions  
 Final Study Visit  
Final Study V isit (Visit 4, Day 60+5)   
The following surveys will be administered for visit four:  
Surveys administered to the PWD are indicated by [CONTACT_457659]:  
 
o PAINAD  (If QDRS >12)  
o FAM -CAM  
o BPI ( If QDRS <12). 
o QOL -AD (If QDRS <12) 
o NPI-Q 
o CGQOL:  
o Public Health Questionnaire 9 (PHQ -9) 
o Zarit Burden Inventory  
o SF-12 
o Charlson Comorbidity  
o Resource Utilization Inventory  
  Page 28 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 28 APR 2017  o HHCAHPS  
o Katz ADLs and Lawton IADLS (through the QOL- AD) 
o Non- instrumented: Medication Record and Usage,  Resource Utilization Inventory , AE and SAE  
o Information obtained from the chart includes: Number of visits by [CONTACT_457657],  comorbidities , COVID -[ADDRESS_584665]’s health record, including OASIS documentation, symptom scores, assessment information, and administrative visit 
information.  
 Withdrawal/Early Termination Visit  
Should individuals withdraw from the study for any reason, we will attempt to ask for the reason and ask if any SAE or AE have occurred if the PWD/caregiver are reachable. We will also if  withdrawal is for non-
communication with the study team we will review the HHC medical record to ascertain if there was an SAE or AE.  
7.3 Concomitant Medications, Treatments, and Procedures  
Not Applicable  
7.4 Justification for Sensitive Procedures  
There are no sensitive procedures, provocative testing or deception inherent in this study.  
7.5 Prohibited Medications, Treatments, and Procedures  
Not applicable  
7.6 Prophylactic Medications, Treatments, and Procedures  
Not applicable  
7.7 Rescue Medications, Treatments, and Procedures 
Not applicable  
7.8 Participant Access to Study Agent at Study Closure  
Not applicable. Should the individual still be receiving HHC from the intervention team at the close of the 
study period they will continue to receive the intervention.  
8 Assessment of Safet y 
8.1 This study is a minimal risk study given that it is an evidence- based implementation science 
intervention. However, the investigators will monitor for the following safety parameters and events 
throughout this study. In instances where an adverse event (AE) or a serious adverse event (SAE) has been identified, the investigators will follow standard clinical practice (SCP) whereby [CONTACT_457660]’s health care provider responsible for initiating and/or approving 
the subject’s enrollment into HHC services. In situations where an AE or SAE has been determined 
to be related to the study and the subject has withdrawn, investigators will actively monitor in follow up.  Specification of Safety Parameters  
 
  Page 29 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 28 APR 2017  Due to the pragmatic nature of the trial, the DSMB has directed this trial to perform a highly focused AE 
collection process which requires following single adverse event: a PHQ -9 score worsened by [CONTACT_216729] 5 points during the course of the study. The DSMB further requires monitoring the following severe AEs: Caregiver attempted suicide; death of caregiver; death of person with dementia a; medical event that may jeopardize the subject, including hospi[INVESTIGATOR_457592], suicidal ideation, elder neglect or abuse, or an environmental threat such as unsecured firearm.  
 In cases of the following safety parameters, the site- PI [INVESTIGATOR_457593] , a telephone 
triage performed, and then SCP will be followed by [CONTACT_457661]’s primary care provider to advise 
of the situation.  
 Due to the virtual nature of data collection, safety monitoring will be done to the best of abilities for:  
Imminent home safety threats/hazards (e.g. hoarding/cluttering, unsecured gun). Suspected elder abuse or neglect.  
 Caregiver Depression: Should caregivers have a score of ≥10 on the PHQ -9 or exhibit suicidal ideation 
via item 9 of the PHQ -9 or verbally outside of any instrumentation, Definition of Adverse Events (AE)  
 
An adverse event  (AE) is any symptom, sign, illness or experience that develops or worsens in severity 
during the course of the study.  Intercurrent illnesses or injuries should be regarded as adverse events.  Abnormal results of diagnostic procedures are considered to be adverse events if the abnormality:  
• results in study withdrawal  
• is associated with a serious adverse event  
• is associated with clinical signs or symptoms  
• leads to additional treatment or to further diagnostic tests 
• is considered by [CONTACT_457662]:  
 Worsening of depression symptoms: Caregivers whose PHQ -9 score worsen by [CONTACT_55559] 5 
points during the course of the study  
 Definition  of Serious Adverse Events (SAE)  
Serious Adverse Event  
Adverse events are classified as serious or non- serious.  A serious adverse event  is any AE that is:  
• fatal 
• life-threatening  
• requires or prolongs hospi[INVESTIGATOR_4408]  
• results in persistent or significant disability or incapacity  
• a congenital anomaly or birth defect  
• an important medical event  
 Important medical events are those that may not be immediately life threatening but are clearly of major clinical significance. They may jeopardize the subject and may require intervention to prevent one of the other serious outcomes noted above. For example, drug overdose or abuse, a seizure that did not result in 
in-patient hospi[INVESTIGATOR_059], or intensive treatment of bronchospasm in an emergency department would 
typi[INVESTIGATOR_15355].  
 
All adverse events that do not meet any of the criteria for serious should be regarded as non -serious 
adverse events.  
 
The following SAEs will be monitored in this study:  
 
  Page 30 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 28 APR 2017  Caregiver attempted suicide: A case in which a caregiver is noted to have attempted suicide. This 
information may be provided by [CONTACT_457663], PWD (if only mild dementia) or other family member, 
friend, or caregiver when attempting to complete follow -up visits.  
 
Death of Caregiver: A case in which a caregiver is noted to have died. This information may be provided by [CONTACT_457663], PWD (if only mild dementia) or other family member, friend, or caregiver when attempting to complete follow -up visits. We will attempt to ascertain the cause of death of the caregiver  
 
Death of PWD: A case in which the PWD has died. We will attempt to contact [CONTACT_457664].  
 Any SAE will be immediately reported to the site- PI [INVESTIGATOR_457594], who will follow SCP by [CONTACT_457665]’s health care provider and then notifying the IRB of record and DSMB for further review.  
 Definition of Unanticipated Problems (UP)  
 Unanticipated Problems Involving Risk to Subjects or Others  
Any incident, experience, or outcome that meets all  of
  the following criteria:  
• Unexpected in nature, severity, or frequency  (i.e. not described in study -related documents such 
as the IRB -approved protocol or consent form, the investigators brochure, etc)  
• Related or possibly related to participation in the research ( i.e. possibly related means there is a 
reasonable possibility that the incident experience, or outcome may have been caused by [CONTACT_3459])  
• Suggests that the research places subjects or others at greater risk of harm  (
 including physical, 
psychological, economic, or social harm).  
 T
his definition could include an unanticipated serious adverse effect on health or safety or any life-
threatening problem or death caused by, or associated with, the intervention, if that effect, problem, or death was not previously identified in nature, severity, or degree of incidence in the investigational plan or application (including a supplementary plan or application), or any other unanticipated serious problem associated with a device that relates to the rights, safety, or welfare of subjects (21 CFR 812.3( s)). 
 
8.2 Classification of an Adverse Event  
 Severity of Event  
 For AEs not included in the protocol defined grading system, the following guidelines will be used to describe severity.  
 
• Mild – Events require minimal or no treatment and do not interfere with the participant’s daily 
activities.  
• Moderate  – Events result in a low level of inconvenience or concern with the therapeutic 
measures. Moderate events may cause some interference with func tioning.  
• Severe  – Events interrupt a participant’s usual daily activity and may require systemic drug 
therapy or other treatment. Severe events are usually potentially life- threatening or incapacitating.  
 
 Relationship to Study Quality Improvement Program  
 
 
  Page 31 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 28 APR 2017  The PI [INVESTIGATOR_457595]'s relationship to study quality improvement program, and will be  part of 
the documentation process, but it is not a factor in determining what is or is not reported in the study. If 
there is any doubt as to whether a clinical observation is an AE, the event should be reported. All AEs must 
have their relationship to study agent assessed. In a clinical trial, the study product must always be suspect. To help assess, the following guidelines are used.  
 
• Related – The AE is  known to occur with the study agent, there is a reasonable possibility that the 
study agent caused the AE, or there is a temporal relationship between the study agent and event. Reasonable possibility means that there is evidence to suggest a causal relationship between the study agent and the AE.  
• Not Related  – There is not a reasonable possibility that the administration of the study agent 
caused the event, there is no temporal relationship between the study agent and event onset, or an alternate etiology  has been established.  
 
 Expectedness 
 The site PI [INVESTIGATOR_457596]. An AE will be considered unexpected if the nature, severity, or frequency of the event is not consistent with the risk 
information previously described for the study agent.  
8.3 Time Period and Frequency for Event Assessment and Follow -Up 
The occurrence of an AE or SAE may come to the attention of study personnel during study visits and 
interviews of a study participant presenting for medical care, or upon review by a study monitor. All AEs including local and systemic reactions not meeting the criteria for SAEs will be captured on the appropriate RF. Information to be collected includes event description, time of onset, clinician’s  assessment of severity, 
relationship to study product (assessed only by [CONTACT_8703] a diagnosis), 
and time of resolution/stabilization of the event. All AEs occurring while on study must be documented 
appropriately regardless of relationship. All AEs will be followed to adequate resolution.  
 Any medical condition that is present at the time that the participant is screened will be considered as baseline and not reported as an AE. However, if the study participant’s condition deteriorates at any time during the study, it will be recorded as an AE. UPs will be recorded in the data collection system throughout 
the study.  
 
Changes in the severity of an AE will be documented to allow an assessment of the duration of the event at each level of severity to be performed. AEs characterized as intermittent require documentation of onset 
and duration of each epi[INVESTIGATOR_1865].  
 
The PI [INVESTIGATOR_118632] 7 (for non- serious AEs) or 30 days (for SAEs) after the last day of study participation. At each study 
visit, the investigator will inquire about the occurrence of AE/SAEs since the last visit Events will be followed for outcome information until resolution or stabilization.  
 
All unresolved adverse events should be followed by [CONTACT_1374], the 
subject is lost to follow -up, or the adverse event is otherwise explained.  At the last scheduled visit, the 
investigator should instruct each subject to report any subsequent event(s) that the subject, or the subject’s personal physician, believes might reasonably be related to participation in this study.  The investigator should notify the study sponsor of any death or adverse event occurring at any time after a subject has discontinued or terminated study participation that may reasonably be related to this study.  The sponsor 
should also be notified if the investigator should become aware of the development of cancer or of a 
congenital anomaly in a subsequently conceived offspring of a subject that has participated in this study.  
  Page 32 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 28 APR 2017  8.4 Reporting Procedures – Notifying the IRB  
 
All AEs and SAEs will be reported to the site- P I (if applicable) and study -PI [INVESTIGATOR_97318]. The PI [INVESTIGATOR_457597], consult with the co -investigators  if necessary, and when an event has been 
determined to be severe, the site PI [INVESTIGATOR_457598]’s health care provider. The PI 
[INVESTIGATOR_457599] 24 hours of their knowledge of the incident.  The 
PI [INVESTIGATOR_457600], IRB, site- PIs and other individuals regarding related SAE 
to the trial. All AEs will be recorded and reviewed immediately and for patterns of AE on a quarterly basis and referred with a corresponding report to the IRB and DSMB . 
 Unanticipated Problem Reporting  
 Incidents or events that meet the OHRP criteria for UPs require the creation and completion of an UP report 
form. It is the site inves tigator’s responsibility to report UPs to their IRB and to the DSMB/study sponsor. 
The UP report will include the following information:  
 
• Protocol identifying information: protocol title and number, PI’s name, and the IRB project number;  
• A detailed description of the event, incident, experience, or outcome;  
• An explanation of the basis for determining that the event, incident, experience, or outcome 
represents an UP;  
• A description of any changes to the protocol or other corrective actions that have been taken or 
are proposed in response to the UP.  
 
To satisfy the requirement for prompt reporting, UPs will be reported using the following timeline:  
 
• UPs that are SAEs will be reported to the IRB and to the DSMB/study sponsor within 24 hours of 
the investigator becoming aware of the event.  
• Any other UP will be reported to the IRB and to the DSMB/study sponsor within 3 days of the 
investigator becoming aware of the problem.  
• All UPs should be reported to appropriate institutional officials (as required by [CONTACT_17347]’s 
written reporting procedures), the supporting agency head (or designee), and OHRP within<insert timeline in accordance with policy> of the IR’s receipt of the report of the problem from the 
investigator.  
 
8.5 Reporting Procedures – Notifying the Study Sponsor  
 
The study clinician will complete a SAE Form within the following timelines:  
 
• All deaths and immediately life- threatening events, whether related or unrelated, will be recorded 
on the SAE Form.  SAE that have been determined to be related to the study will be submitted to the DSMB/study sponsor within [ADDRESS_584666] information.  
• Other SAEs that are determined to be related to the study will be submitted to the DSMB/study sponsor within 72 hours of site awareness.  
 All SAEs will be followed until satisfactory resolution or until the site investigator deems the event to be 
chronic or the adherence to be stable. Other supporting documentation of the event may be requested by 
[CONTACT_4318]/study sponsor and should be provided as soon as possible.  
 As a follow -up to the initial report, within the following 48 hours  of awareness of the event , the investigator 
shall provide further information, as applicable, on the unanticipated event or the unanticipated problem in the form of a written narrative.  This should include a copy of the completed Unanticipated Problem form, 
  Page 33 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: [ADDRESS_584667] the understanding of the event.  Significant new 
information on ongoing unanticipated adverse  effects shall be provided promptly to the study sponsor.  
 
8.6 Reporting Procedures – Participating Investigators  
As noted in 8.4 all site PIs will take part in the classification of AEs, SAEs and UPs and will therefore be immediately contact[CONTACT_457666].  
 
8.7 Study Halting Rules  
Temporary suspension of the trial will occur if there is a 20% or greater negative effect found in any of the  
primary outcomes. The study will also be halted if SAEs are found that are caused by [CONTACT_457667], or at the discretion of the IC or the DSMB in conjunction with the IC. Safety Oversight  
 
It is the responsibility of the Principal Investigator [INVESTIGATOR_16462]/her site.  This safety monitoring will include careful assessment and appropriate reporting of adverse events as noted above, as well as the construction and implementation of a site data and safety -monitoring plan. Medical 
monitoring will include a regular assessment of the number and type of serious adverse events.  
 
8.[ADDRESS_584668] in an advisory capacity to the Primary IC  Director in regards to the study.  
 
 Frequency and Reporting 
 As noted in section 8.4 , all AE and SAE will be reported directly to the site PI [INVESTIGATOR_457601]. All events 
will be reported within 24 hours to the DSMB and the IRB at both the study site and the primary IRB (NYU). The DSMB will then discuss whether and how to convene. Outside of SAE, the DSMB will meet at least prior to onset of the trial and every 6 months at a minimum. Safety reports will be sent twice yearly including  
analysis of study progress and data and safety issues. These reports will include descriptive analyses of  
participant demographic data, interim analyses of primary and secondary outcomes, as well as any adverse or serious adverse events, and quality improvement program  fidelity. Individuals who withdraw from the 
trial will be examined in sensitivity analyses, however will be replaced with completed cases for the 
purposes of the trial. There are no cases where the quality improvement program  will be discontinued but 
follow -up will still occur unless an individual withdraws  from the study due to an AE or SAE, in which case 
we will ensure safety of the individual/dyad and referral to existing resources.  
 Data Safety and Monitoring Board  
[IP_ADDRESS].1  DSMB Composition  
 The investigators  will develop with the IC a 3- member independent DSMB. The composition will include a 
chair who has experience performing Phase III behavioral clinical trials in dementia, a biostatistician, and 
an independent clinician- researcher with experience in home- based care of older adults. All members will 
  Page 34 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: [ADDRESS_584669] 3 years.  
 
[IP_ADDRESS].[ADDRESS_584670] of the study  or enrollment, sample size, or data collection issues. The quality improvement 
program  will be discontinued or temporarily halted  if the IC closes the trial or DSMB recommends 
discontinuing or halting the trial based on determining the  study’s subjects (care recipi[INVESTIGATOR_457602]) 
safety is compromised or at risk. ( see section 8.7 ). 
  
[ADDRESS_584671] of the trial is in compliance with the currently approved protocol/amendment(s), with GCP, and with applicable regulatory requirement(s). As this is a minimal risk study, limited clinical monitoring will be performed by [CONTACT_457668], the lead site principal 
investigator [INVESTIGATOR_457603]. As noted in fidelity 
measurement, we will also hold monthly meetings to ensure quality improvement program fidelity. Additionally, each research site wil l perform internal quality management of study conduct, data collection, 
documentation and completion.  
 
10 Statistical Considerations  
10.1 Statistical and Analytical Plans (SAP)  
A formal SAP will not be completed for this study.  
 
10.2 Statistical Hypotheses 
H1: PWD ca red for by a HHC team utilizing the DSM- H will show reduced symptoms and improved ratings 
of pain, BPSD, and caregiver -rated QOL at the end of the first 60- day HHC certification period compared 
to the control (usual care) group.  
 H2: Informal caregivers of  PWD cared for by a HHC team utilizing the DSM- H will show reduced ratings of 
burden, and depression, and improved functional health and well -being at the end of the first 60- day HHC 
certification period compared to the control (usual care) group.  
 
H3: PWD  cared for by a HHC team utilizing the DSM- H will show a reduction in emergency room visits and 
hospi[INVESTIGATOR_457572] (usual care) group, and a greater number of outpatient visits.  
 
  Page 35 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: [ADDRESS_584672] a separate data set. Additionally, a data set with combined 
will be created to examine the interaction between PWD -caregiver dyad interactions and interactions 
between outcomes and quality improvement program fidelity. Separate SAE and AE data sets will be 
maintained for caregivers and PWDs.  
 
10.4 Description of Statistical Methods  
 General Approach  
 Data Analysis  will be performed using SAS 9. 4
120. We will perform statistical tests to examine baseline 
differences between the quality improvement program and control groups . We will then perform unadjusted 
comparison of both primary outcomes (patient and caregiver quality of life, emergency room visits) and secondary outcomes (pain, BPSD, delirium, caregiver depression burden, and burnout, hospi[INVESTIGATOR_457604]) between groups.  We will focus on the endpoint measure for quality of life, 
and 30 and 60- day outcomes for emergency room utilization. For primary and secondary outcomes, we will 
perform a time trend analysis using a mixed effects linear model (PROC MCM). Mixed effects regression 
is used to analyze longitudinal data with repeated measures accounting for intra- individual and group 
clustering. We intend to use multivariate mixed effects regression modeling as opposed to traditional linear modeling or ANOVA in order to control for unobservable confounding variables that are constant over time 
but differ across PWD and/or caregivers
121. For both primary and secondary outcomes, we will then repeat 
the above analyses adjusting for baseline variables as covariates for a more efficient measurement of the 
effects of the quality improvement program. We will also perform correlation analyses to explore the relationship between pain and BPSD, and PWD and caregiver QOL through plotting scores over time and then if a significant correlation is present through adding to our mixed effect model. For utilization data, w e 
will perform logistic regression to examine whether the patient is more or less likely to have a hospi[INVESTIGATOR_457605] [ADDRESS_584673] to measure for clustering.  
 Safety Analyses  
We will perform interim analyses using descriptive statistics and two-s ided t -tests, monitoring for a 
significance of 0.05 starting at the end of year 1 of the grant for safety purposes. These results will be presented unblinded to the DSMB.  
 Adherence and Retention Analyses  
We will perform sensitivity analyses to examine whether there are differences in those who are retained in the study vs those who withdraw/are terminated. As this is a cluster randomized trial, adherence is related to the quality improvement program implementation at the care team level and therefore falls under fidelity monitoring. We will examine differences in annual DSKA scores submitted by [CONTACT_457669] t -tests and repeated measures ANOVA.  
 Baseline Descriptive Statistics  
We will c ompare quality improvement program cohorts based on baseline demographic variables 
including age, sex, education, race, ethnicity, healthcare literacy, functional status, and comorbidities 
using descriptive statistics and t -tests.  
 
 Planned Interim Analysis  
See. 10.4.2  
  Page 36 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 28 APR 2017  [IP_ADDRESS]  Safety Review  
See 8.7 and 10.4.2 . 
 
[IP_ADDRESS]  Efficacy Review  
See 10.4.2 . Efficacy will not be considered i n halting the study.  
 
 Additional Sub -Group Analyses  
We will perform sub- group analyses based on age, sex, and race/ethnicity. We will perform both 
descriptive and multivariate comparisons.  
 
 Multiple Comparison/Multiplicity  
Not Applicable  
 
 Tabulation of Individual Response Data  
Individual participant data will not be listed, with the exception of spaghetti plots of change over time.  
 
 Exploratory Analyses  
We will examine the effect of ADL function on non- QOL outcomes. We will also examine the interaction of 
caregiver and PWD primary and secondary outcomes.  
10.[ADDRESS_584674] recent clustered palliative care 
study123 and aligns well with prior community -based cluster trials124. The Quality of Life in Alzheimer’s 
Disease as the primary outcome measure in aim [ADDRESS_584675] deviation difference in this measure would be clinically meaningful. Therefore, in a 2- sample 
comparison with a power of .80, an alpha of .05 and covariates that account for a cumulative 15% of the 
variance in outcome would require 15 dyads per cluster, and 20 clusters (10 per arm) at [ADDRESS_584676]  (δ = .45). For mixed effects linear models, the projected sample size will also allow us to 
detect a medium linear treatment effect (δ = .45) between groups in unadjusted analyses (assuming 15 dyads per cluster, 20 clusters, 4 observations, and an ICC = .05). Although there are no closed- form 
equations for calculating the power of linear models that include covariates, any non- zero correlation 
between covariates and the outcome will reduce the unexplained (error) variance thus increasing the 
statistical po wer of our tests, and reducing the minimum detectable effect size. As such, the detectable 
effect size estimated for the unadjusted analyses can be considered an upper bound estimate for the jneffect size detectable in adjusted analyses. We will recruit un til we have reached 15 completed cases 
in each cluster (N=300). Conservatively  anticipating a 15% dropout
40,[ADDRESS_584677] 20,000 patients are seen each year in the three HHC agencies 
in this study, approximately 30% with ADRD, we do not expect any difficult recruiting this sample, even with an unanticipatedly high rate of dyads declining to participate.   
 In addition, for fidelity monitoring, as discussed in section [IP_ADDRESS] , we will consent 3
 00 clinicians  at the 
participating HHC agencies on usual care and quality improvement care teams to complete fidelity monitor 
by [CONTACT_457670]. These clinicians are not study subjects but will be consented as they are 
  Page 37 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: [ADDRESS_584678] the research team in monitoring fidelity of the quality improvement 
program.  
10.6 Measures to Minimize Bias  
 Enrollment/Randomiz ation/Masking Procedures 
As randomization is done at the cluster (care team) level, this will only be performed at the beginning of the trial. The study statistician will perform the randomization utilizing SAS 9.[ADDRESS_584679] method described above in section 5.4. 
 Clinicians will be enrolled sequentially if they are eligible and all study personnel with the exception of the lead site PI [INVESTIGATOR_457606] a performance improvement or usual care team.  
 
 Evaluation of Success of Blinding  
Not applicable  
 
 Breaking the Study Blind/Participant Code  
Intentional breaking of the blind will only be performed in case of SAE, and then only to the site PI, but not the site RA or project director.  
 
11 Source Documents and Access to Source Data/Documents  
 
Source data is all information, original records of clinical findings, observations, or other activities in a 
clinical trial necessary for the reconstruction and evaluation of the trial.  Source data are contained in source 
documents.  Examples of these original documents, and data records include: hospi[INVESTIGATOR_1097], clinical and office charts, laboratory notes, memoranda, subjects’ diaries or evaluation checklists, pharmacy dispensing records, recorded data from automated instruments, copi[INVESTIGATOR_10379], microfiches, photographic negatives, microfilm or magnetic media, x -rays, 
subject files, and records kept at the pharmacy, at the laboratories, and at medico- technical departments 
involved in the clinical trial.  It is acceptable to use CRFs as source documents. If this is the case, it should 
be stated in this section what data will be collected on CRFs and what data will be collected from other sources.  
 All assessment data, which has no PHI,  will be collected using Qualtrics, which is hosted by [CONTACT_457671] . Any data with PHI will  be collected and entered directly  into REDCap, which is hosted by [CONTACT_457672]. In order to access REDCap or Qualtrics, you must use your NYULMC or NYU  
login credential respectively to access through a secure portal. Data will be transferred from Qualtrics to 
REDCap by [CONTACT_240583]. All Qualtrics assessments will require a forced entry to ensure missing data is minimized  
 
PHI will only be collected in Redcap. A study ID will be created in NYU REDCap and used for all Qualtrics 
data that is collecting surveys. Once data is collected, it will be downloaded from Qualtrics to a NYU MCIT -
managed network drive on a weekly basis that will only be accessible to the appropriate study personnel 
  Page 38 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: [ADDRESS_584680] It is HIPA A compliant and approved by [CONTACT_457673].  
 
Data will be collected electronically through the use of computers or utilizing iPADs that are owned, centrally managed, passcode required, and distributed to the study RAs acros s sites by [CONTACT_457674] . The iPads will 
be encrypted and locked so that only secure and approved apps, such as for collecting data offline (Qualtrics App) will be made available. Once data is collected through the use of  Qualtrics  surveys , it can 
only be transferred to the secure Qualtrics server and not extracted by [CONTACT_11174]. Thus, when the iPad 
is connected to secure wifi, the data will be automatically uploaded to the Qualtrics server and removed 
from the iPad.  Electronic informed consent documents with s ubject information will be collected, stored and 
maintained on the REDCap system.  
 
Access to study records will be limited to IRB -approved members of the study team. The investigator will 
permit study -related monitoring, audits, and inspections by [CONTACT_1201]/EC, the sponsor, government regulatory 
bodies, and University compliance and quality assurance groups of all study related documents (e.g. source 
documents, regulatory documents, data collection instruments, study data etc.).  The investigator will ensure the capability for inspections of applicable study -related facilities (e.g. pharmacy, diagnostic 
laboratory, etc.).  
 Participation as an investigator in this study implies acceptance of potential inspection by [CONTACT_28832].  
12 Quality Assurance and Quality Control  
 
QC procedures will be implemented beginning with the data entry system and data QC checks that will be run on the database will be generated. Any missing data or data anomalies will be communicated to the site(s) for clarification/resolution.  
 
The lead PI [INVESTIGATOR_457607], documented (recorded), 
and reported in compliance with the protocol, and GCP in coordination with the study statistician.  
 The investigational site will provide direct access to all trial related sites, source data/documents, and reports for the purpose of monitoring and auditing by [CONTACT_456], and inspection by [CONTACT_3482].  
 
13 Ethics/Protection of Human Subjects  
13.[ADDRESS_584681]  
 The investigator will ensure that this study is conducted in full conformity with Regulations for the Protection of Human Subjects of Research codified in 45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, and/or the ICH E6.  
 
13.[ADDRESS_584682]  
 The protocol, informed consent form(s), recruitment materials, and all participant materials will be submitted to the IRB for review and approval. Approval of both the protocol and the consent form must be obtained before any participant is enrolled. Any amendment to the protocol will require review and approval by [CONTACT_3484]. All changes to the consent form will be IRB approved; a determination will be made regarding whether previously consented participants need to be re- consented.  
 
  Page 39 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 28 APR 2017  13.3 Informed Consent Process  
 Consent/Assent and Other Informational Documents Provided to Participants  
 
Consent forms describing in detail the quality improvement program, study procedures, and risks are 
provided to each participant electronically through the REDCap database. The completion of all consent documents will include electronic signatures that will be obtained and maintained through the REDCap system prior to starting st udy-related activities. The following consent materials are submitted with this 
protocol.  
 Consent -PWD  
Assent Form -PWD  
Consent -Caregiver  
Telephone Consent Script -PWD Surrogate  
Application for Waiver of documentation of consent -PWD  and Caregiver  
Applicatio n for Waiver of Documentation of Informed Consent -Clinician  
Study Information Survey Header -Clinician  
 Consent Procedures and Documentation  
 
Informed consent is a process that is initiated prior to the individual’s agreeing to participate in the study 
and continues throughout the individual’s study participation. Extensive discussion of risks and possible benefits of participation will be provided to the participants and their families. Consent forms will be IRB -
approved and the participant will be asked to read and review the document. The investigator will explain the research study to the participant and answer any questions that may arise. All participants will receive a verbal explanation in terms suited to their comprehension of the purposes, procedures, and potential risks of the study and of their rights as research participants.  Following the COVID -[ADDRESS_584683] ( PI; IRB) with questions , and that their participation is voluntary  and 
can be stopped at any time without consequence to the PLWD’s treatment. The participants are given an  
opportun ity to discuss the study with their surrogates or think about it prior to agreeing to participate. 
Participants will have the opportunity to carefully review the electronic  consent form and ask questions prior 
to signing and/or providing verbal consent . The participant will electronically sign the informed consent 
document prior to any procedures being done specifically for the study.  Only i n cases where the subject 
due to lack of internet or poor computer literacy  cannot electronically sign the consent for m, we will accept 
their verbal consent to participate after all information on the consent document has been presented to them ensuring that regulatory HIPAA language has been heard and all questions have been answered. In 
these situations where verbal consent is received, the research will date and sign the informed consent 
document and advise the participant of their enrollment status, confirm with the subject that they want to 
participate, and then ask the subject if the researcher may begin the visit one assessments.  In the cases 
where verbal consent, as a secondary option has been provided by [CONTACT_2299], a copy of the consent form completed with the researcher’s signature [CONTACT_457688] 2. Where one part of the caregiver -PWD dyad can sign electronically and the other cannot, we will 
capture the signature [CONTACT_457689], and verbal consent of the individual who cannot  
following said process, as they may be in different locations with differential access to internet.  The 
participants may withdraw consent at any time throughout the course of the trial. A copy of the  electronically 
signed informed consent document will be downloaded by [CONTACT_457675]. The rights and  
welfare of the participants will be protected by [CONTACT_34693].  
 
  Page 40 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: [ADDRESS_584684]’s research record on 
REDCap. The consent process, including the name [CONTACT_21811], will be thoroughly 
documented in the subject’s research record. Any alteration to the standard consent process (e.g. use of a 
translator, consent from a legally authorized representative, consent document presented orally, etc.) and the justification for such alteration will likewise be documented.  
 Consent will be performed remotely by [CONTACT_457676]. Deter mination of 
capacity for consent is discussed in section 5.[ADDRESS_584685]’s informed consent will be collected electronically and stored in the subject record on REDCap. If the PWD does not have capacity, and verbal or electronic consent is provided by [CONTACT_457677], the PWD will be asked f or their assent.  
 I
n addition to consent, in PWD who are determined to lack capacity, we will ask for their assent if they are 
verbally able to do so. If they chose not to assent, we will not enroll them in the study.  
   
13.[ADDRESS_584686] of 1996 (HIPAA). Those regulations require a signed subject authorization informing the subject of the following:  
 
• What protected health information (PHI) will be collected from subjects in this study  
• Who will have access to that information and why 
• Who will use or disclose that information  
• The rights of a research subject to revoke their authorization for use of their PHI.  
 
In the event that a subject revokes authorization to collect or use PHI, the investigator, by [CONTACT_5151], retains 
the ability to use all information collected prior to the revocation of subject authorization.  For subjects that have revoked authorization to collect or use PHI, attempts should be made to obtain permission to collect at least vital status (i.e. that the subject is alive) at the end of their scheduled study period.  
 Participant confidentiality is strictly held in trust by [CONTACT_3486], their staff, and the 
sponsor(s) and their agents. This confidentiality is extended to cover testing of biological samples and 
genetic tests in addition to the clinical information relating to participants. Therefore, the study protocol, documentation, data, and all other information generated will be held in strict confidence. No information concerning the study or the data will be released to any unauthorized third party without prior written 
approval of the sponsor.  
 Authorized representatives of the sponsor and representatives of the IRB may inspect all documents and records required to be maintained by [CONTACT_093], including but not limited to, medical  records (office, 
clinic, or hospi[INVESTIGATOR_307]) and pharmacy records for the participants in this study. The clinical study site will permit access to such records.  
 
The study participant’s contact [CONTACT_162694]. At the end of the study, all records will continue to be kept in REDCAP or an MCIT managed networked drive for as long a period as dictated by [CONTACT_46202].  
 Study participant research data, which is for  purposes of statistical analysis and scientific reporting, will be 
transmitted to and stored at NYU Langone Medical Center and the NYU School of Nursing. Transmission 
from external sites will be performed securely through the MCIT managed iPADs, or through secure 
  Page 41 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 28 APR 2017  encrypted email. This will not include the participant’s contact [CONTACT_1290]. Rather, individual 
participants and their research data will be identified by a unique study identification number. The study 
data entry and study management systems used by [CONTACT_457678]. At the end of the study, all study databases will be de-identified and archived at the NYU Langone Medical Center and NYU School of Nursi ng.  
 Research Use of Stored Human Samples, Specimens, or Data  
Not Applicable  
 
13.[ADDRESS_584687] to receive an email or text message to reminder them of upcoming study 
visits, will receive a notification through REDCap.  Email notifications will be performed using REDCap 
survey function.  SMS (text) messages will  be completed through a linked REDCap and Twilio account.  
When a subject requests to receive a text message to their cell phone, REDCap requests that action 
through Twilio. When the subject responds to the message, Twilio relays the information back to RE DCap. 
The data from this exchange is stored in the REDCap database. Twilio does not store any data nor does it 
keep a log of its actions.  Further, REDCap goes to great length to ensure that SMS transcriptions do not 
stay in Twilio’s logs but are removed shortly after being completed. This is done for security and privacy 
concerns (e.g., HIPPA), in which the subject’s phone number and response to confirm the visit are not 
permanently logged on Twilio’s servers but instead remain securely in REDCap.  
 
 D
ata collection is the responsibility of the clinical trial staff at the site under the supervision of the site PI. 
The investigator is responsible for ensuring the accuracy, completeness, legibility, and timeliness of the data reported.  
 All source documents should be completed in a neat, legible manner to ensure accurate interpretation of data. Black ink is required to ensure clarity of reproduced copi[INVESTIGATOR_014]. When making changes or corrections, cross out the original entry with a single line, and initial and date the change. DO NOT ERASE, 
OVERWRITE, OR USE CORRECTION FLUID OR TAPE ON THE ORIGINAL.  
 
Copi[INVESTIGATOR_58625] (eCRF) will be provided for use as source documents and maintained for recording data for each participant enrolled in the study. Data reported in the eCRF derived from source documents should be consistent with the source documents or the discrepancies should be explained and captured in a progress note and maintained in the participant’s official electronic study record.  
 Clinical data (incl uding AEs, concomitant medications, and expected adverse reactions data) and clinical 
laboratory data will be entered into RedCap, a [ADDRESS_584688] 
  Page 42 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 28 APR 2017  protection and internal quality checks, such as automatic range checks, to identify data that appear 
inconsistent, incomplete, or inaccurate. Clinical data will be entered directly from the source documents.  
 
14.2 Study Records Re tention  
Study documents will be retained for the longer of 3 years after close- out, 5 years after final 
reporting/publication.  
14.3 Protocol Deviations  
 A protocol deviation is any noncompliance with the clinical trial protocol, GCP, or Manual of Procedures (MOP) requirements. The noncompliance may be either on the part of the participant, the investigator, or 
the study site staff. As a result of deviations, corrective actions are to be developed by [CONTACT_3483].  
 These practices are consis tent with ICH E6:  
• 4.5 Compliance with Protocol, sections 4.5.1, 4.5.2, and 4.5.3  
• 5.1 Quality Assurance and Quality Control, section 5.1.1  
• 5.20 Noncompliance, sections 5.20.1, and 5.20.2.  
 It is the responsibility of the site PI/study staff to use continuous vigilance to identify and report deviations within [ADDRESS_584689] be reported to the local IRB per their guidelines. The site PI/study staff is responsible for knowing and adhering to their IRB requirements. Further details about the handling of 
protoc ol deviations will be included in the MOP.  
 
14.4 Publication and Data Sharing Policy  
 
This study will comply with the NIH Public Access Policy, which ensures that the public has access to the published results of NIH funded research. It requires scientists to submit final peer -reviewed journal 
manuscripts that arise from NIH funds to the digital archive PubMed Central upon acceptance for 
publication.  
 
The International Committee of Medical Journal Editors (ICMJE) member journals have adopted a clinical trials re gistration policy as a condition for publication. The ICMJE defines a clinical trial as any research 
project that prospectively assigns human subjects to intervention or concurrent comparison or control groups to study the cause- and-effect relationship bet ween a medical intervention and a health outcome. 
Medical interventions include drugs, surgical procedures, devices, behavioral treatments, process -of-care 
changes, and the like. Health outcomes include any biomedical or health- related measures obtained in  
patients or participants, including pharmacokinetic measures and adverse events. The ICMJE policy, and the Section [ADDRESS_584690] of 2007, requires that all clinical trials be registered in a public trials registry such as ClinicalTrials.gov, which is sponsored by [CONTACT_118702]. Other biomedical journals are considering adopting similar policies. For interventional 
clinical trials performed under NIH IC grants and cooperative agreements, it is the grantee’s responsibility to register the trial in an acceptable registry, so the research results may be considered for publication in ICMJE member journals. The ICMJE does not review specific studies to determine whether registration is necessary; instead, the committee recommends that researchers who have questions about the need to 
  Page 43 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 28 APR 2017  register err on the side of registration or consult the editorial office of the journal in which they wish to 
publish.  
 The trial will be registered through clinicaltrials.gov prior to starting.  
 The investigators will follow the NIH policy on making available an anonymized, publicly available data set following conclusion of the study.  
15 Study Finances  
15.1 Funding Source  
This study is financed through a grant from the US National Institutes of Health.  
15.2 Costs to the Participant  
There will be no costs to participate outside of usual care that is performed.  
15.3 Participant  Reimbursements or Payments  
PWD and caregivers will each receive $25 gift cards at visits 1 and 4 and $[ADDRESS_584691] with this study (patent ownership, royalties, or financial gain 
greater than the minimum allowable by [CONTACT_1385], etc.) must have the conflict reviewed by [CONTACT_46205] (CIMU)  with a Committee- sanctioned conflict management 
plan that has been reviewed and approved by [CONTACT_28833]. All NYULMC  investigators will follow the applicable conflict of interest policies . 
 
 
  Page 44 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 28 APR 2017  17 References  
1. [LOCATION_002] Census Bureau. Annual Projections of the Resident Population by [CONTACT_31365], Sex, Race, 
and Hispanic Origin: Lowest, Middle, Highest Series and Zero International Migration Series, 1999 to 2100. 2004; http://www.census.gov/population/www/projections/natdet -D1A.html . 
2. Barnes DE, Covinsky KE, Whitmer RA, Kuller LH, Lopez OL, Yaffe K. Predicting risk of dementia 
in older adults: The late- life dementia risk index. Neurology. Jul 21 2009;73(3):173 -179. DOI: 
10.1212/WNL.0b013e3181a81636  
3. Institute of Medicine. Retooling for an Aging America: Building the Health Care Workforce. 
Washington, D.C.: Institute of Medicine;2008.  
4. Department of H ealth and Human Services. National Plan to Address Alzheimer's Disease: 2016 
Update. Washington, DC2016.  
5. Joynt J. Beds for Boomers: Will Hospi[INVESTIGATOR_457608]. Oakland: [LOCATION_004] Healthcare 
Foundation;2008.  
6. Murtaugh C, Peng T, Totten A, Costello B, Moore S, Aykan H. Complexity in geriatric home healthcare. Journal for healthcare quality : official publication of the National Association for 
Healthcare Quality. Mar -Apr 2009;31(2):34- 43.  
7. Herr KA, Garand L. Assessment and measurement of pain in older adults. Clinics in Geriatric 
Medicine. 2001;17(3):457- 478.  
8. Van Someren EJW. Circadian and sleep disturbances in the elderly. Exp. Gerontol. 2000;35(9-
10):1229- 1237.  
9. McCurry SM, Reynolds CF, Ancoli -Israel S, Teri L, Vitiello MV. Treatment of sleep  disturbance in 
Alzheimer's disease. Sleep Medicine Reviews. 2000;4(6):603- 628.  
10. Montorio I, Izal M. The Geriatric Depression Scale: A Review of Its Development and Utility. Int. Psychogeriatr. 2005;8(01):103- 112.  
11. Narici MV, Maganaris CN, Reeves N D, Capodaglio P. EFFECT OF AGING ON HUMAN 
MUSCLE ARCHITECTURE. J. Appl. Physiol. 2003:4332003.  
12. Gibson SJ, Farrell M. A Review of Age Differences in the Neurophysiology of Nociception and the 
Perceptual Experience of Pain. The Clinical Journal of Pain.  2004;20(4):227.  
13. Redfield MM, Jacobsen SJ, Borlaug BA, Rodeheffer RJ, Kass DA. Age- and Gender -Related 
Ventricular -Vascular Stiffening A Community -Based Study. Vol 112: Am Heart Assoc; 2005:2254-
2262.  
14. Craik FIM, McDowd JM. Age Differences in Recall and Recognition. Age. 2007;278:739.  
15. Wenzel LB, Fairclough DL, Brady MJ, et al. Age- related differences in the quality of life of breast 
carcinoma patients after treatment. Cancer. 1999;86(9):1768- 1774.  
16. Gibson SJ, Helme RD. Age -related differences in pain perception and report. Clinics in Geriatric 
Medicine. 2001;17(3):433- 456.  
17. Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the Beers Criteria 
for Potentially Inappropriate Medication Use in Older Adults Results of a US Consensus Panel of Experts. Vol 163: Am Med Assoc; 2003:2716- 2724.  
18. Rosenstock J. Management of Type 2 Diabetes Mellitus in the Elderly: Special Considerations. 
Drugs Aging. 2001;18(1):31.  
19. Stoltz P, Ud en G, Willman A. Support for family carers who care for an elderly person at home- a 
systematic literature review. Scand. J. Caring Sci. 2004;18(2):111- 119.  
20. Sha MC, Callahan CM, Counsell SR, Westmoreland GR, Stump TE, Kroenke K. Physical 
symptoms as a predictor of health care use and mortality among older adults. The American 
Journal of Medicine. 2005;118(3):301- 306.  
21. Pi[INVESTIGATOR_6259], Strandberg TE, Tilvis RS. Management of Nonmalignant Pain in Home- Dwelling 
Older People: A Population -Based Survey. Geriatrics. 2002;50(11):1861- 1865.  
22. Hanlon JT, Landerman LR, Wall WE, et al. Is Medication Use by [CONTACT_328619] -dwelling Elderly 
People Influenced by [CONTACT_457679]? Age Ageing. 1996;25(3):190- 196.  
23. Yong HH, Gibson SJ, de L. Horne DJ, Helme RD. Development of a Pain Attitudes Questionnaire 
to Assess Stoicism and Cautiousness for Possible Age Differences. Journals of Gerontology 
Series B: Psychological Sciences and Social Sciences. 2001;56(5):279- 284.  
  Page 45 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 28 APR 2017  24. Glajchen M, Bookbinder M. Knowledge and perceived competence of home care nurses in pain 
management: a national survey. J Pain Symptom Manage. Apr 2001;21(4):307- 316.  
25. Brody AA, Guan C, Cortes T, Galvin JE. Development and testing of the Dementia Symptom 
Management at Home (DSM- H) program: An interprofessional home health care intervention to 
improve the quality of life for persons with dementia and their caregivers. Geriatr Nurs. May-Jun 
2016;37(3):200- 206. DOI: 10.1016/j.gerinurse.2016.01.[ADDRESS_584692] heat sensitivity and reports of unpleasantness in communicative people with mild to moderate cognitive impairment in Alzheimer's disease: a 
cross- sectional study. BMC Med. 2016;14:74. DOI: 10.1186/s12916- 016-0619-1 
27. American Geriatrics Society. The management of persistent pain in older persons. AGS panel on 
persistent pain in older persons. J. Am. Geriatr. Soc. Jun 2002;50(s6):205- 224.  
28. Morrison RS, Magaziner J, Gilbert M, et al. Relationship between pain and opi[INVESTIGATOR_457609]. J. Gerontol. A. Biol. Sci. Med. Sci. Jan 
2003;58(1):76- 81.  
29. Morrison RS, Magaziner J, McLaughlin MA, et al. The impact of post -operative pain on outcomes 
following hip fracture. Pain. Jun 2003;103(3):303- 311. DOI: S030439590200458X [pii]  
30. Daltroy LH, Larson MG, Eaton HM, Phillips CB, Liang MH. Discrepancies between self -reported 
and observed physical function in the elderly: the influence of response shift and other factors. Soc. Sci. Med. 1999;48(11):1549- 1561.  
31. Foley  SJ, Lord SR, Srikanth V, Cooley H, Jones G. Falls risk is associated with pain and 
dysfunction but not radiographic osteoarthritis in older adults: Tasmanian Older Adult Cohort study. Osteoarthritis Cartilage. 2006;14(6):533- 539.  
32. Steinberg M, Shao H,  Zandi P, et al. Point and 5- year period prevalence of neuropsychiatric 
symptoms in dementia: the Cache County Study. Int. J. Geriatr. Psychiatry. Feb 2008;23(2):170-
177. DOI: 10.1002/gps.1858 
33. White HK, McConnell ES, Bales CW, Kuchibhatla M. A 6- month observational study of the 
relationship between weight loss and behavioral symptoms in institutionalized Alzheimer's 
disease subjects. Journal of the American Medical Directors Association. Mar -Apr 2004;5(2):89-
97. DOI: 10.1097/01.JAM.[PHONE_9599].[ZIP_CODE].EF  
34. Peters KR, Rockwood K, Black SE, et al. Neuropsychiatric symptom clusters and functional disability in cognitively -impaired- not-demented individuals. The American journal of geriatric 
psychiatry : official journal of the American Association for Geriatr ic Psychiatry. Feb 
2008;16(2):136- 144. DOI: 10.1097/JGP.0b013e3181462288  
35. Ballard C, Lowery K, Powell I, O'Brien J, James I. Impact of Behavioral and Psychological Symptoms of Dementia on Caregivers. Int. Psychogeriatr. 2000;12(SupplementS1):93- 105. DOI : 
doi:10.1017/S1041610200006840  
36. Gaugler JE, Wall MM, Kane RL, et al. The effects of incident and persistent behavioral problems 
on change in caregiver burden and nursing home admission of persons with dementia. Med. 
Care. Oct 2010;48(10):875- 883. DOI: 10.1097/MLR.0b013e3181ec557b  
37. Chan WC, Lam LC, Tam CW, et al. Neuropsychiatric symptoms are associated with increased 
risks of progression to dementia: a 2- year prospective study of 321 Chinese older persons with 
mild cognitive impairment. Age Ageing. Jan 2011;40(1):30- 35. DOI: 10.1093/ageing/afq151  
38. Kong EH, Evans LK, Guevara JP. Nonpharmacological intervention for agitation in dementia: a 
systematic review and meta- analysis. Aging & Mental Health. Jul 2009;13(4):512- 520. DOI: 
10.1080/13607860902774394  
39. Salzman C, Jeste DV, Meyer RE, et al. Elderly patients with dementia- related symptoms of 
severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy. The Journal of clinical psychiatry. Jun 2008;69(6):889- 898.  
40. Gitlin LN, Winter L, Dennis MP, Hodgson N, Hauck WW. A Biobehavioral Home- Based 
Intervention and the Well -being of Patients With Dementia and Their Caregivers. JAMA: The 
Journal of the American Medical Association. 2010;304(9):983- 991.  
41. Okura T, Langa KM. Caregiver burden and neuropsychiatric symptoms in older adults with cognitive impairment: the Aging, Demographics, and Memory Study (ADAMS). Alzheimer Dis. 
Assoc. Disord. Apr-Jun 2011;25(2):116- 121. DOI: 10.1097/WAD.0b013e318203f208  
  Page 46 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 28 APR 2017  42. Etters L, Goodall D, Harrison BE. Caregiver burden among dementia patient caregivers: a review 
of the literature. J. Am. Acad. Nurse Pract. Aug 2008;20(8):423- 428. DOI: 10.1111/j.1745-
7599.2008.[ZIP_CODE].x  
43. Murman DL, Chen Q, Powell MC, Kuo SB, Bradley CJ, Colenda CC. The incremental direct costs associated with behavioral symptoms in AD. Neurology. Dec 10 2002;59(11):1721- 1729.  
44. DeKosky ST, Orgogozo JM. Alzheimer disease: diagnosis, costs, and dimensions of treatment. Alzheimer Dis. Assoc. Disord. Aug 2001;[ADDRESS_584693] 1:S3- 7.  
45. Miaskowski C, Dodd M, Lee K. Symptom clusters: the new frontier in symptom management 
research. J Natl Cancer Inst Monogr. 2004(32):17- 21.  
46. Dodd MJ, Miaskowski C, Lee KA. Occurrence of symptom clusters. J Natl Cancer Inst Monogr. 
2004(32):76- 78.  
47. Mavandadi S, Ten Have TR, Katz IR, et al. Effect of depression treatment on depressive 
symptoms in older adulthood: the moderating role of pain. J Am Geriatr Soc. Feb 2007;55(2):202-
211.  
48. Beck SL, Dudley WN, Barsevick A. Pain, sleep disturbance, and fatigue in patients with cancer: using a mediation model to test a symptom cluster. Oncol Nurs Forum. May 2005;32(3):542.  
49. Haasum Y, Fastbom J, Fratiglioni L, Kareholt I, Johnell K. Pain treatment  in elderly persons with 
and without dementia: a population- based study of institutionalized and home- dwelling elderly. 
Drugs Aging. Apr 1 2011;28(4):283- 293. DOI: 10.2165/11587040- 000000000- [ZIP_CODE]  
50. Fishbain DA, Cutler R, Rosomoff HL, Rosomoff RS. Chroni c Pain -Associated Depression: 
Antecedent or Consequence of Chronic Pain? A Review. The Clinical Journal of Pain. 
1997;13(2):116- 137.  
51. Lin EHB, Katon W, Von Korff M, et al. Effect of Improving Depression Care on Pain and 
Functional Outcomes Among Older Adults With Arthritis: A Randomized Controlled Trial. JAMA. 
November 12, 2003 2003;290(18):2428- 2429. DOI: 10.1001/jama.290.18.2428  
52. Bair MJ, Robinson RL, Katon W, Kroenke K. Depression and Pain Comorbidity: A Literature 
Review. Arch Intern Med. November 10, 2003 2003;163(20):2433- 2445. DOI: 
10.1001/archinte.163.20.2433  
53. Daltroy LH, Larson MG, Eaton HM, Phillips CB, Liang MH. Discrepancies between self -reported 
and observed physical function in the elderly: the influence of response shift and other factors. Soc Sci Med. Jun 1999;48(11):1549- 1561. DOI: S0277953699000489 [pii]  
54. Volicer L, Frijters DHM, Van der Steen JT. Relationship between symptoms of depression and agitation in nursing home residents with dementia. Int. J. Geriatr. Psychiatry. 2011:n/a- n/a.  
55. Friedman EM, Shih RA, Langa KM, Hurd MD. US Prevalence And Predictors Of Informal Caregiving For Dementia. Health Aff. (Millwood). Oct 2015;34(10):1637- 1641. DOI: 
10.1377/hlthaff.2015.0510  
56. Alzheimer's Association. 2016 Alzheimer's Disease Facts and Figures. Chicago, IL: Alzheimer's 
Association;2016.  
57. National Academies of Sciences Engineering and Medicine. Families Caring for an Aging 
America. Washington, D.C.: National Academies of Sciences Engineering and Medicine;2016.  
58. Kim H, Cha ng M, Rose K, Kim S. Predictors of caregiver burden in caregivers of individuals with 
dementia. J. Adv. Nurs. 2012;68(4):846- 855. DOI: 10.1111/j.1365- 2648.2011.[ZIP_CODE].x  
59. Chin AL, Negash S, Hamilton R. Diversity and disparity in dementia: the impact of et hnoracial 
differences in Alzheimer disease. Alzheimer Dis. Assoc. Disord. Jul -Sep 2011;25(3):187- 195. 
DOI: 10.1097/WAD.0b013e318211c6c9  
60. Gurland BJ, Wilder DE, Lantigua R, et al. Rates of dementia in three ethnoracial groups. Int. J. Geriatr. Psychiatry . 1999;14(6):481- 493. DOI: 10.1002/(SICI)1099- 1166(199906)14:6<481::AID -
GPS959>3.0.CO;2-5 
61. Mahoney DF, Cloutterbuck J, Neary S, Zhan L. African American, Chinese, and Latino Family Caregivers' Impressions of the Onset and Diagnosis of Dementia: Cross -Cultural Similarities and 
Differences. The Gerontologist. December 1, 2005 2005;45(6):783- 792. DOI: 
10.1093/geront/45.6.783  
62. Livney MG, Clark CM, Karlawish JH, et al. Ethnoracial differences in the clinical characteristics of 
Alzheimer's disease at initial presentation at an urban Alzheimer's disease center. Am. J. Geriatr. Psychiatry. May 2011;19(5):430- 439. DOI: 10.1097/JGP.0b 013e3181f7d881  
  Page 47 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 28 APR 2017  63. Chen JC, Borson S, Scanlan JM. Stage- specific prevalence of behavioral symptoms in 
Alzheimer's disease in a multi -ethnic community sample. Am. J. Geriatr. Psychiatry. Spring 
2000;8(2):123- 133.  
64. Mausbach BT, Coon DW, Depp C, et al. Ethnicity and time to institutionalization of dementia 
patients: a comparison of Latina and Caucasian female family caregivers. J. Am. Geriatr. Soc. Jul 
2004;52(7):1077- 1084. DOI: 10.1111/j.1532- 5415.2004.[ZIP_CODE].x  
65. Scott WK, Edwards KB, Davis DR, Cornman CB, Macera CA. Risk of institutionalization among community long- term care clients with dementia. Gerontologist. Feb 1997;37(1):46- 51.  
66. Brody AA, Galvin JE. A review of interprofessional dissemination and education interventions for recognizing and managing dementia. Gerontol. Geriatr. Educ. 2013;34(3):225- 256. DOI: 
10.1080/02701960.2013.[ADDRESS_584694] of a dementia care management intervention on primary care provider knowledge, attitudes, and perceptions of quality of care. J. Am. Geriatr. Soc. Feb 
2006;54(2):311- 317. DOI: 10.1111/j.1532- 5415.2005.[ZIP_CODE].x  
68. Ellis IK, Philip T. Improving the skills of rural and remote generalists to manage mental health 
emergencies. Rural Remote Health. Jul -Sep 2010;10(3):1503.  
69. Gallagher M. Evaluating a protocol to train hospi[INVESTIGATOR_457610]. Int 
J Palliat Nurs. Apr 2011;17(4):195- 201.  
70. Galvin JE, Kuntemeier B, Al -Hammadi N, Germino J, Murphy -White M, McGillick J. "Dementia-
friendly Hospi[INVESTIGATOR_600]: Care not Crisis": An Educational Program Designed to Improve the Care of the 
Hospi[INVESTIGATOR_457611]. Alzheimer Dis. Assoc. Disord. Jul 9 2010. DOI: 
10.1097/WAD.0b013e3181e9f829  
71. McAiney CA, Stolee P, Hillier LM, et al. Evaluation of the sustained implementation of a mental 
health learning initiative in long- term care. International psychogeriatrics / IPA. Oct 
2007;19(5):842- 858. DOI: 10.1017/S1041610206004443  
72. Meuser TM, Carr DB, Berg- Weger M, Niewoehner P, Morris JC. Driving and dementia in older 
adults: Implementation and evaluation of a continuing education project. The Gerontologist. Oct 
2006;46(5):680- 687.  
73. Barton C, Miller B, Yaffe K. Improved evaluation and management of cognitive impairment: 
results of a comprehensive interventi on in long- term care. Journal of the American Medical 
Directors Association. Feb 2006;7(2):84- 89. DOI: 10.1016/j.jamda.2005.06.008  
74. Cherry DL, Hahn C, Vickrey BG. Educating primary care physicians in the management of Alzheimer's disease: using practice guidelines to set quality benchmarks. International 
psychogeriatrics / IPA. Apr 2009;[ADDRESS_584695] 1:S44- 52. DOI: 10.1017/S1041610209008692  
75. Chrzescijanski D, Moyle W, Creedy D. Reducing dementia- related aggression through a staff 
education intervention. De mentia. May 1, 2007 2007;6(2):271- 286. DOI: 
10.1177/1471301207080369 
76. Downs M, Turner S, Bryans M, et al. Effectiveness of educational interventions in improving 
detection and management of dementia in primary care: cluster randomised controlled study. 
BMJ. Mar 25 2006;332(7543):692- 696. DOI: 10.1136/bmj.332.7543.[ADDRESS_584696] of an interdisciplinary educational program on antipsychotic prescribing among nursing home residents with dementia. Int. J. Geriatr. Psyc hiatry. 
Jun 2008;23(6):574- 579. DOI: 10.1002/gps.1934  
78. Ray WA, Taylor JA, Meador KG, et al. Reducing Antipsychotic Drug Use in Nursing Homes: A Controlled Trial of Provider Education. Arch Intern Med. March 22, 1993 1993;153(6):713- 721. 
DOI: 10.1001/arc hinte.1993.[ADDRESS_584697], Pi[INVESTIGATOR_101659], et al. Translation of the Care of Persons with Dementia in their 
Environments (COPE) intervention in a publicly -funded home care context: Rationale and 
research design. Contemporary clinical trials. Jul 2016;49:155- 165. DOI: 
10.1016/j.cct.2016.07.006  
80. Jones AJ, Harris -Kojetin L, Valverde R. Characteristics and use of home health care by [CONTACT_457680] 65 and over. Atlanta, GA: Centers for Disease Control and Prevention;2012.  
81. Samus QM, Johnston D, Black BS, et al. A multidimensional home- based care coordination 
intervention for elders with memory disorders: the Maximizing Independence at Home (MIND) 
  Page 48 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 28 APR 2017  pi[INVESTIGATOR_37087]. Am. J. Geriatr. Psychiatry. Apr 2014;22(4):398- 414. DOI: 
10.1016/j.jagp.2013.12.175  
82. Bruce ML, Raue PJ, Reilly CF, et al. Clinical effectiveness of integrating depression care 
management into medicare home health: the Depression CAREPATH Randomized trial. JAMA 
Intern Med. Jan 2015;175(1):55- 64. DOI: 10.1001/jamainternmed.2014.5835  
83. Bakitas MA, Tosteson TD, Li Z, et al. Early Versus Delayed Initiation of Concurrent Palliative 
Oncology Care: Patient Outcomes in the ENABLE III Randomized Controlled Trial. J. Clin. Oncol. 
May 1 2015;33(13):1438- 1445. DOI: 10.1200/JCO.2014.58.6362  
84. Dionne- Odom JN, Azuero A, Lyons KD, et al. Benefits of Early Versus Delayed Palliative Care to 
Informal Family Caregivers of Patients With Advanced Cancer: Outcomes From the ENABLE III 
Randomized Controlled Trial. J. Clin. Onco l. May 1 2015;33(13):1446- 1452. DOI: 
10.1200/JCO.2014.58.[ADDRESS_584698] J, et al. Translating and testing the ENABLE: CHF -PC 
concurrent palliative care model for older adults with heart failure and their family caregivers. J Palliat  Med. Sep 2014;17(9):995- 1004. DOI: 10.1089/jpm.2013.0680  
86. Bakitas M, Lyons KD, Hegel MT, et al. Effects of a palliative care intervention on clinical 
outcomes in patients with advanced cancer: the Project ENABLE II randomized controlled trial. 
JAMA. Aug 19 2009;302(7):741- 749. DOI: 10.1001/jama.2009.[ADDRESS_584699] ENABLE II randomized controlled trial to 
improve palliative care for rural patients with advanced cancer: baseline findings, methodological 
challeng es, and solutions. Palliative & supportive care. Mar 2009;7(1):75- 86. DOI: 
10.1017/S1478951509000108  
88. Bakitas M, Stevens M, Ahles T, et al. Project ENABLE: a palliative care demonstration project for 
advanced cancer patients in three settings. J Palliat  Med. Apr 2004;7(2):363- 372. DOI: 
10.1089/[ADDRESS_584700] 2 years of life. 
Ann. Intern. Med. Nov 2 2010;153(9):563- 569. DOI: 10.7326/0003- 4819- 153-9- 201011020- [ZIP_CODE]  
91. Saliba D, Buchanan J. Making the investment count: revision of the Minimum Data Set for nursing homes, MDS 3.0. J Am Med Dir Assoc. Sep 2012;13(7):602- 610. DOI: 
10.1016/j.jamda.2012.06.002  
92. Enache D, Winblad B, Aarsland D. Depression in dementia: epi[INVESTIGATOR_623], mechanisms, and treatment. Current opi[INVESTIGATOR_61626]. Nov 2011;24(6):461- 472. DOI: 
10.1097/YCO.0b013e32834bb9d4  
93. Czajkowski SM, Powell LH, Adler N, et al. From ideas to efficacy: The ORBIT model for developi[INVESTIGATOR_388194]. Health Psychol. Oct 2015;34(10):971- 982. 
DOI: 10.1037/hea0000161  
94. Corbeil RR, Qu ayhagen MP, Quayhagen M. Intervention Effects on Dementia Caregiving 
Interaction: A Stress -Adaptation Modeling Approach. J. Aging Health. February 1, 1999 
1999;11(1):79- 95. DOI: 10.1177/089826439901100105 
95. Zwakhalen SM, Hamers JP, Peijnenburg RH, Berger  MP. Nursing staff knowledge and beliefs 
about pain in elderly nursing home residents with dementia. Pain Res Manag. Autumn 
2007;12(3):177- 184.  
96. Davison TE, McCabe MP, Mellor D, Karantzas G, George K. Knowledge of late- life depression: 
an empi[INVESTIGATOR_457612]. Aging & Mental Health. Jul 2009;13(4):577- 586. 
DOI: 10.1080/[ADDRESS_584701] 
Nonpharmacological Interventions for Treatment of Behavior Symptoms Associated With Dementia: A Comparison of Physicians, Psychologists, and Nurse Practitioners. The 
Geront ologist. Nov 9 2011. DOI: 10.1093/geront/gnr081 
98. Brody AA, Cortes T, Galvin JE. Helpi[INVESTIGATOR_457613]: A site- controlled trial of the Dementia Symptom Management at Home 
Program. In Review.  
  Page 49 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: [ADDRESS_584702]? The validity and 
reliability of the Quality of Life- Alzheimer's Disease (QoL- AD) scale. Alzheimer Dis. Assoc. 
Disord. Oct -Dec 2003;17(4):201- 208.  
100. Vickrey BG, Hays RD, Maines M L, Vassar SD, Fitten J, Strickland T. Development and 
preliminary evaluation of a quality of life measure targeted at dementia caregivers. Health Qual 
Life Outcomes. 2009;7:56. DOI: 10.1186/1477- 7525-7- [ADDRESS_584703]: 
pharmacoeconomics: assessing health- related resource use among healthy elderly. Alzheimer 
Dis. Assoc. Disord. Oct -Dec 2006;20([ADDRESS_584704] 3):S191- 202. DOI: 
10.1097/01.wad.[PHONE_9600].[ZIP_CODE].87  
102. Kaufer DI, Cummings JL, Ketchel P, et al. Validation of the NPI -Q, a brief clinical form of the 
Neuropsychiatric Inventory. J. Neuropsychiatry Clin. Neurosci. Spring 2000;12(2):233- 239. DOI: 
10.1176/jnp.12.2.233  
103. Tan G, Jensen MP, Thornby [CONTACT_163692], Shanti BF. Validation of the Brief Pain Inventory for chronic 
nonmalignant pain. J Pain. Mar 2004;5(2):133- 137. DOI: 10.1016/j.jpain.2003.12.005  
104. Kroenke K, Spi[INVESTIGATOR_4280], Williams JB. The PHQ -9: validity of a brief depression severity measure. 
J. Gen. Intern. Med. Sep 2001;16(9):606- 613.  
105. Beda rd M, Molloy DW, Squire L, Dubois S, Lever JA, O'Donnell M. The Zarit Burden Interview: a 
new short version and screening version. The Gerontologist. Oct 2001;41(5):652- 657.  
106. Center for Medicare and Medicaid Services. OASIS Based Home Health Agency Patient 
Outcome and Case Mix Reports. Washington, D.C.2011.  
107. Zhu CW, Scarmeas N, Ornstein K, et al. Health- care use and cost in dementia caregivers: 
Longitudinal results from the Predictors Caregiver Study. Alzheimers Dement. Apr 
2015;11(4):444- 454. DOI:  10.1016/j.jalz.2013.12.018  
108. Borson S, Scanlan JM, Chen P, Ganguli M. The Mini -Cog as a screen for dementia: validation in 
a population- based sample. Journal of the American Geriatrics Society. Oct 2003;51(10):1451-
1454.  
109. Palmer BW, Dunn LB, Appelbaum PS, et al. Assessment of capacity to consent to research 
among older persons with schizophrenia, Alzheimer disease, or diabetes mellitus: comparison of 
a 3-item questionnaire with a comprehensive standardized capacity instrument. Arch. Gen. 
Psychiatry. Jul 2005;62(7):726- 733. DOI: 10.1001/archpsyc.62.7.726  
110. Mezey MD, Kobayashi M, Grossman S, Firpo A, Fulmer T, Mitty E. Nurses Improving Care to Health System Elders (NICHE): implementation of best practice models. J. Nurs. Adm. Oct 
2004;34(10):451- 457. DOI: 00005110- 200410000- [ZIP_CODE] [pii]  
111. King HB, Battles J, Baker DP, et al. TeamSTEPPS: Team Strategies and Tools to Enhance 
Performance and Patient Safety. In: Henriksen K, Battles JB, Keyes MA, Grady ML, eds. 
Advances in Patient Safety: New Directions and Alternative Approaches (Vol. 3: Performance and Tools) . Rockville (MD)2008.  
112. Marshall S, Harrison J, Flanagan B. The teaching of a structured tool improves the clarity and content of interprofessional clinical communication. Qual Saf Health Care. Apr 2009;18(2):137-
140. DOI: 18/2/137 [pii]  
10.1136/qshc.2007.025247  
113. Volicer L, Hurley AC. Review Article: Management of Behavioral Symptoms in Progressive Degenerative Dementias. The Journals of Gerontology Series A: Biological Sciences and Medical  
Sciences. September 1, 2003 2003;58(9):M837- M845. DOI: 10.1093/gerona/58.9.M837  
114. Alexopoulos GS, Abrams RC, Young RC, Shamoian CA. Cornell scale for depression in dementia. Biol. Psychiatry. 2/1/ 1988;23(3):271- 284. DOI: http://dx.doi.org/10.1016/0006-
3223(88)[ZIP_CODE]-8  
115. Burke WJ, Roccaforte WH, Wengel SP. The short form of the Geriatric Depression Scale: a comparison with the 30- item form. J. Geriatr. Psychiatry Neurol. Jul -Sep 1991;4(3): 173-178.  
116. Warden V, Hurley AC, Volicer L. Development and Psychometric Evaluation of the Pain Assessment in Advanced Dementia (PAINAD) Scale. Journal of the American Medical Directors 
Association. 1// 2003;4(1):9 -15. DOI: http://dx.doi.org/10.1016/S1525- 8610(04)[ZIP_CODE]-3  
117. Robinson BC. Validation of a Caregiver Strain Index. J. Gerontol. May 1983;38(3):344- 348.  
  Page 50 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 28 APR 2017  118. Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M. Developi[INVESTIGATOR_457614]: the new Medical Research Council guidance. Int. J. Nurs. Stud. May 
2013;50(5):587- 592. DOI: 10.1016/j.ijnurstu.2012.09.010  
119. Galvin JE. The Quick Dementia Rating System (Qdrs): A Rapid Dementia Staging Tool. 
Alzheimers Dement (Amst). Jun 01 2015;1(2):249- 259. DOI: 10.1016/j.dadm.2015.03.003  
120. SAS/STAT Statistical Analysis Software [computer program]. Version 9.3. Cary, NC: SAS 
Institute, Inc.,; 2013.  
121. Allison PD. Fixed Effects Regression Methods In SAS.2006, Proceedings of the Thirty -first 
Annual SAS Users Group International Conference.  
122. Optimal Design Plus Empi[INVESTIGATOR_124591] [computer program]. Version 3.[ZIP_CODE].  
123. Zimmermann C, Swami N, Krzyzanowska M, et al. Early palliative care for patients wit h advanced 
cancer: a cluster -randomised controlled trial. Lancet. May 17 2014;383(9930):1721- 1730. DOI: 
10.1016/S0140- 6736(13)[ZIP_CODE]-2 
124. Campbell MK, Mollison J, Steen N, Grimshaw JM, Eccles M. Analysis of cluster randomized trials 
in primary care: a practical approach. Fam. Pract. April 1, 2000 2000;17(2):192- 196. DOI: 
10.1093/fampra/17.2.[ADDRESS_584705] of a Disease Management Intervention on 
Quality and Outcomes of Dementia CareA Randomized, Controlled Trial. Ann. Intern. Med. 
2006;145(10):713- 726. DOI: 10.7326/0003- 4819- 145-10-200611210- [ZIP_CODE]  
126. Marcantonio ER, Ngo LH, O'Connor M, et al. 3D -CAM: derivation and validation of a 3- minute 
diagnostic interview for CAM- defined delirium: a cross -sectional diagnostic test study. Ann. Intern. 
Med. Oct 21 2014;161(8):554- 561. DOI: 10.7326/M14- 0865  
127. Jenk inson C, Layte R, Jenkinson D, et al. A shorter form health survey: can the SF -12 replicate 
results from the SF -36 in longitudinal studies? Journal of Public Health. June 1, 1997 
1997;19(2):179- 186.  
128. Lee SY, Stucky BD, Lee JY, Rozier RG, Bender DE. Short Assessment of Health Literacy -
Spanish and English: a comparable test of health literacy for Spanish and English speakers. 
Health Serv. Res. Aug 2010;45(4):1105- 1120. DOI: 10.1111/j.1475- 6773.2010.[ZIP_CODE].x  
129. Katz S, Downs TD, Cash HR, Grotz RC. Progress in development of the index of ADL. Gerontologist. Spring 1970;10(1):20- 30.  
130. Lawton MP, Brody EM. Assessment of older people: self -maintaining and instrumental activities 
of daily living. Gerontologist. Autumn 1969;9(3):179- 186.  
131. Lieffers JR, Baracos VE, Winget M, Fassbender K. A comparison of Charlson and Elixhauser 
comorbidity measures to predict colorectal cancer survival using administrative health data. 
Cancer. May 1 2011;117(9):1957- 1965. DOI: 10.1002/cncr.[ZIP_CODE]  
  
  Page 51 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 28 APR 2017  18 Attachments  
These documents are relevant to the protocol, but they are not considered part of the protocol.  They are 
stored and modified separately. As such, modifications to these documents do not require protocol amendments.  
 
• Consent Form -PWD  
• Consent Form -Caregiver  
• Assent F orm-PWD  
• Application for Temporary Waiver of documentation of consent -PWD  
• Application for Waiver of Documentation of Consent -Clinicians  
• Vulnerable Populations: Cognitive Impaired Subject Appendix  
• Study Manual  
• Assessment Instruments -PWD/Caregiver Dyads  
• Dementia Symptom Knowledge Assessment -Clinicians  
• Originally Submitted Grant  
• Follow -up requested modifications by [CONTACT_457681]  
• COVID Questionnaire  
• Email and text templates  
 
Study number:  s17-[ZIP_CODE]   Page 52 
Version:  1.9   
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in 
writing by [CONTACT_110810]: 05 JAN 2017  
 19 Schedule of Events  
  Page 53 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in 
writing by [CONTACT_110810]: 28 APR 2017  Table 2 . Variables and Timing of Data Collection  from PWD -Caregiver Dyads  
Variable  Instruments or Measures  Items  Min.  Timing of Data Collection (Days)  
Patient  Caregiver  
0 15 30 60 0 15 30 60 
Consent            
Patient -Centered Outcomes            
Stage of Dementia  Quick Dementia Rating Scale119 10 5         
BPSD  Neuropsychiatric Inventory 
Questionnaire  13 5         
Quality of life  Quality of Life in Alzheimer’s 
Disease99 13 5         
Pain Brief Pain Inventory Short Form  9 5         
Pain  PAINA D 5 3         
Patient Satisfaction  HHCAHPS  32 7         
Pain Analgesic use (collected by [CONTACT_457682])  1 1         
BPSD  Antipsychotic use (collected by [CONTACT_457683])  
 1 1         
Delirium  FAM -CAM126 11 3         
Caregiver Centered Outcomes            
Quality of Life  Caregiver Targeted Quality of 
Life100 80 20         
Depression  Public Health Questionnaire 9104 9 3         
Burden  Zarit Burden Inventory105 22 10         
Health  SF-[ZIP_CODE] 12 3         
Utilization Outcomes             
Healthcare Utilization  Resource Utilization  Inventory101 13 5         
Sociodemographics             
Sociodemographics  Date of birth, sex, education, race, 
ethnicity  6 4         
Language , Religion  and 
Culture  Primary language, religion, literacy 
(SAHL -SE)128 3 3         
Supports             
Social Support  Marital status, household members  2 <1         
Other unpaid caregivers  # individuals, # visits, #hrs/week  3 1         
Paid Caregiver  # visits, hrs/week  2 1         
Home nurse visits  # visits (chart)  1          
Physical/occupational therapy  # visits (chart)  2          
COVID -19 Effects on 
Caregiving  University of Pi[INVESTIGATOR_457615]  18 6         
Health and Functional Status            
Functional Status  Katz Activities of Daily Living129, 
Lawton Instrumental  Activities of 
Daily Living130  12 2         
Comorbidities  Charlson comorbidity 
Questionnaire131    (chart for p atient, 
interview for caregiver)  17 3         
  Page 54 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in 
writing by [CONTACT_110810]: [ADDRESS_584706] Redcap 
database                       
Hire and Train RAs                       
Implement HHC EHR 
changes                       
Finalize sites, cluster 
randomization                       
Identify and train 
champi[INVESTIGATOR_457616] -champi[INVESTIGATOR_457617] ------------- >       
Dyad enrollment                       
Quality Improvement  
fidelity monitoring                       
Clinician Knowledge and 
Attitudes Assessment                       
Data collection                       
DSMB meetings                       
Data analysis                       
Manuscripts and 
Dissemination                       
 